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Chapter 1
Global prevalence of hepatitis B
Hepatitis B virus (HBV) infection causes inflammation of the liver. The majority 
of morbidity and mortality is caused by the increased risk for liver cirrhosis, liver 
failure and liver cancer in chronically infected persons.1 Transmission of the virus is 
possible by blood-blood contact, mother-to-child transmission (MTCT) and sexual 
contact. A strong inverse related relationship exists between the age at infection 
and the development of chronic hepatitis B (CHB) infection with a probability of 
89% of becoming a carrier after an infection within the first six months in life.2 This 
percentage of chronic hepatitis B carrier state diminishes to 5 to 10% with an onset 
of HBV infection in immunocompetent adults.3,4,5 Of the estimated 292 million 
chronically infected patients, the majority became infected at birth through MTCT.6,7 
The disease is a major public health problem, particularly in low- and middle income 
countries with globally an estimated 887.000 deaths in 2015. Highest prevalences of 
CHB are seen in the WHO regions of South-East Asia, Africa, and the Western Pacific 
with a prevalence of respectively 3.5%, 5.7%, and 7.2%. A low endemic prevalence 
of CHB is seen in the WHO region of the Americas (0.4%) and the European region 
(1.6%).7 In low endemic countries, transmission of the virus in high-risk groups occurs 
mainly horizontally among men who have sex with men (MSM), commercial sex 
workers and people who use drugs.8,9
Prevention strategies
The main pillars of prevention and control of transmission of hepatitis B according to 
the World Health Organisation (WHO) are vaccination, case finding and treatment, 
prevention of mother-to-child transmission, harm reduction in people who use 
intravenous drugs and measures to ensure safe blood and injection practices. These 
prevention measures have made the global elimination of viral hepatitis a realistic 
goal.10 In 2016 WHO defined a set of priority actions to reduce the burden of disease 
for viral hepatitis and targets for HBV were set at 95% reduction of new cases and 
65% reduction in mortality by 2030.11 Modelling studies further show the necessary 
requirements for global hepatitis B elimination and that some regions with high 
infant vaccination coverage are projected to reach elimination of new infections 
between 2060 and 2070.12 In this thesis we will address two of these prevention 
strategies: hepatitis B vaccination and case finding, and treatment of CHB carriers.
Hepatitis B vaccination
The availability of a safe and effective vaccine enables primary prevention of hepatitis 




To overcome safety issues linked with plasma derived vaccines and enable large 
scale use, second-generation vaccines were developed and licensed in 1986. These 
second-generation vaccines were based on hepatitis B antigen (HBsAg) produced 
by genetically modified yeast cells.14 Second-generation vaccines are predominantly 
used to protect the global population against hepatitis B.15 Third-generation vaccines 
are based on antigens derived from PreS1 and PreS2 proteins in addition to the 
HBsAg. These vaccines induce immunity based on additional neutralising epitopes.16 
However, the use is restricted as these vaccines are more expensive and licensed 
in a limited number of countries compared to the second-generation vaccines.16-18 
Hepatitis B vaccine development continued in search for improved immunogenicity, 
shifting from antigen to adjuvant enhancements of the vaccine. This resulted in 
the registration of novel adjuvanted vaccines based on immunostimulatory DNA 
sequences binding to Toll-like receptor 9 on human immune cells (1018 adjuvant, 
HepB-CpG), or based on a Toll-like receptor 4 agonist containing 3ʹ- deacylated 
monophosphoryl lipid A and aluminium salt (AS04 adjuvant, Fendrix 20 μg)19,20
Since 1992 the WHO has recommended universal hepatitis B vaccination for all 
infants.15 The implementation of universal vaccination for infants can be accompanied 
by a catch-up programme for other age-groups. The implementation of universal 
vaccination for infants without a catch-up programme, leaves older generations 
unvaccinated and therefore still susceptible of getting infected with HBV. For that 
reason, targeted vaccination of adults at risk of HBV infection remains essential 
in many western countries to reduce further transmission.21,22,23 For children a 3- 
or 4-dose schedule and for adults a 3-dose schedule is recommended to induce 
protection against clinically relevant hepatitis B infection (e.g. HBsAg carrier status 
or clinical hepatitis B virus disease). The majority of healthy vaccinees develop a 
protective antibody response, defined by most countries as an antibody titre against 
hepatitis B surface antigen (anti-HBs) of 10 IU/l or more, measured 1–3 months after 
last vaccination.13,24,25 Some countries apply an anti-HBs titre of 100 IU/l or more as 
indication of long-term protection.26,27 Depending on the age of healthy vaccinees, up 
to 30% develop anti-HBs serum levels of less than 10 IU/l after a standard vaccination 
series and are defined as ‘non-responders’28. Well-known risk factors for non-response 
(NR) in healthy persons are obesity, advanced age, male gender, smoking, and 
genetic pre-disposition.29-31 Immunocompromised patients and patients with renal 
insufficiency are at increased risk of NR as well.32-34
Immunological mechanisms of hepatitis B non-response
Response to HBsAg vaccination is associated with certain major histocompatibility 
complex (MHC) phenotypes and presumably inherited in a dominant fashion.35 
The lack of response is most likely antigen specific and HLA class II genes and 
polymorphisms in cytokine genes are associated with non-responsiveness.29,36,37 
Several immunological mechanisms of NR have been studied and can be divided 




histocompatibility complex and the adaptive immune response; ‘antigen processing 
and presentation’, ‘T-helper cell proliferation and differentiation’, ‘regulatory T-cell 
activation’ and the ‘B-cell response’.38,39,40-46 Those studies were inconclusive to explain 
the cause of non-responsiveness after hepatitis B vaccination.47 Most studies were 
based on a single immunological hypothesis and probably did not acknowledge the 
interplay of complex related immunological factors.48 Novel transcriptome analysis 
demonstrate that several genes related to the immune response, metabolism and 
immune regulation were associated with hepatitis B NR.48 Unravelling the age-related 
mechanisms of NR is in an early stage and associated with an increasing inflammation 
status with older age.49,50
In conclusion, the specific immunological mechanisms of NR after hepatitis B 
vaccination are not completely understood. A targeted approach to overcome the 
moderately immunogenic second-generation vaccines is therefore not yet possible. 
Therefore additional strategies are necessary in order to protect risk groups against 
hepatitis B.
Case finding
Case finding is the process of searching for carriers of hepatitis B through testing blood 
samples for markers of hepatitis B infection. International guidelines like the WHO 
and CDC recommend screening for antibodies to hepatitis B core antigen (anti-HBc) 
in high-risk groups who were not vaccinated in infancy, as anti-HBc is a serological 
marker of previous or present HBV infection.51 Additional markers such as hepatitis 
B surface antigen or anti-HBs of possible infection or immunity respectively can be 
included to the testing algorithm to reduce misclassification of screening results.52 
High-risk people are defined by the WHO as: men who have sex with men (MSM), 
commercial sex workers (CSW), heterosexuals with a high rate of partner change, 
household and sexual contacts of people with CHB, people living with hiv, and people 
who use drugs (PWUD). One hand, screening aims to detect susceptible people, who 
are naïve to HBV, and to offer these people vaccination against HBV infection. On 
the other hand, screening in high-risk groups aims to detect individuals who are 
asymptomatic hepatitis B carriers in order to refer and treat them. This is essential 
to reduce HBV related disease morbidity.53 In addition, screening is also performed 
to prevent further transmission to high-risk groups and the general population.54 
Finally, HBV carriers can also be detected by other screening programmes where HBV 
is not the main focus, but merely an additional finding of the screening. Examples 
of these are antenatal screening and screening for blood and organ donors where 
the emphasis is on the primary prevention of the recipients. Despite these screening 
programs, HBV infections remain largely underdiagnosed. Only an estimated 10% of 
the chronically infected patients is diagnosed with hepatitis B.1
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Hepatitis B in the Netherlands
The Netherlands has a low estimated prevalence of CHB infection of 0.2% in the 
general Dutch population.55 A recent study concludes that the CHB prevalence is 
slightly higher (0.34%) however still one of the lowest prevalences in Europe. The 
vast majority of CHB infections originates from first generation migrants.56 Ongoing 
transmission of hepatitis B virus occurs through sexual transmission, predominantly 
among men who have sex with men.8 The incidence of acute hepatitis B declined 
over the past decades (figure 1).
Figure 1. Incidence of acute hepatitis B between men and women in the Netherlands 1976-2019. Source: 
RIVM, OSIRIS.
Even though the Netherlands is a low endemic country for HBV, this viral disease is 
still an important health priority.55 This is because the mortality of HBV infection, 
which almost entirely attributable to CHB infections, has not decreased in the past 




Figure 2. Number of deaths caused by a chronic viral hepatitis B or hepatitis C infection between 2002-
2015 in the Netherlands. Since 2013, classification of the cause-of-death switched from manually to an 
automated process, which caused a shift of the numbers calculated. Vertical lines (|) represent the end of 
2012 and the beginning of 2013. Purple line: attributed mortality caused by chronic hepatitis B infection 
(according to the ‘middle’ population attributable fraction). Source: Hofman R, Nusselder WJ, Veldhuijzen 
IK et al. Sterfte aan chronische hepatitis B en C in Nederland. Ned Tijdschr Geneeskd. 2016;160:D511.
The Netherlands opted initially for a vaccination policy targeted against high-risk 
groups for HBV mainly because of the low prevalence of hepatitis B combined 
with hepatitis B transmission predominantly among high-risk groups. In 1998 a 
vaccination-program free of charge started targeting behavioural risk groups of 
hepatitis B. After a two-year pilot including only part of the Netherlands, the national 
vaccination program commenced in 2002. Initially, four groups were targeted: MSM, 
PWUD, commercial sex workers and heterosexuals with multiple sexual contacts. 
In 2007, heterosexuals with multiple sexual contacts were excluded due to their 
low prevalence of HBV infection. By the end of 2011, the program also stopped 
targeting PWUD because of the low prevalence of past and CHB infection, no ongoing 
transmission of HBV strains associated with people who inject drugs, and a declining 
number of people who inject drugs in the Netherlands.60,61
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Compared to other countries the Netherlands started universal hepatitis B vaccination 
relatively late. In 2011, universal HBV vaccination was included to the Dutch National 
Immunisation Programme. As a result, the previously mentioned targeted high-
risk vaccination programs for an adult population need continuation until HBV 
transmission declines substantially in the targeted risk-group or the immunological 
effects of the childhood HBV vaccination reach an adult population.8,15,62
Case finding of CHB patients occurs in several screening and public health 
programs in addition to specific high risk situations in patient care in the Netherlands. 
A universal antenatal HBV screening program is in place. It is mandatory to test blood 
and organ donors for HBV, and contacts of notified HBV patients are screened as 
well. The previously mentioned targeted vaccination program for behavioural high-
risk groups against HBV started in 2002. In this program the behavioural risk-groups 
are screened for HBV at the first vaccination consultation.63,64,65 The recommended 
individual high-risk situations in patient care to screen for CHB are certain co-
morbidities (e.g. HIV-infection, hepatitis C) or among others the start of in vitro 
fertilisation, chemotherapy or immunosuppressive treatment.
In addition to current screening programs, the Health Council of the Netherlands 
advised in 2016 a parallel three-track approach for screening to detect HBV. This 
approach consists of case finding of chronically infected individuals in risk groups 
by GPs, by institutions delivering care to these risk groups and of screening first-
generation migrants in regions with relatively large migrant populations.66 Prior to 
the Health Council’s advice, independent small outreach screening projects had 
taken place among several first-generation migrant groups in the Netherlands.67-69 
This patchwork of laborious screening projects had a variable, however limited 
reach, depending on the method used of approaching the migrant group. As yet, 
no structural screening program is in place directed at first-generation migrants in 
the Netherlands.
Thesis aims
Preventive measures against hepatitis B, such as vaccination and case finding by 
means of active hepatitis B virus (HBV) testing in the Netherlands can reduce the 
burden of disease for HBV. The first part of the thesis aims to provide insights to the 
knowledge gaps existing in prevention of hepatitis B through vaccination (chapters 
2-5). The second part of the thesis addresses case finding by means of active hepatitis 
B virus (HBV) testing in the Netherlands (chapters 6-7). The outcomes are intended 
to strengthen the evidence base for recommendations in current and future HBV 
guidelines.
For vaccination to be effective, completion of a full primary series of three 
vaccinations is important. Chapter 2 describes the results of ten years of active HBV 




the results of factors associated with completion of a primary vaccination schedule 
against hepatitis B in people who use drugs in the Netherlands.
Antibodies against hepatitis B surface antigen (anti-HBs) are the correlate of 
protection against hepatitis B virus after vaccination. In chapter 3 we use data from 
a quality assurance program (SKML) for anti-HBs assays to assess whether clinically 
relevant differences in commercially available assays exist around clinically important 
cut-off values.
Non-response after hepatitis B vaccination is relatively frequently encountered 
in an adult population. To address the optimal revaccination policy, in chapter 4 
we present data from a multi-centre randomised controlled trial comparing the 
immunogenicity of three alternative vaccines in hepatitis B non-responders after a 
primary series against the standard revaccination schedule.
In chapter 5 we explore the hypothesis that the height of the pre-revaccination 
(baseline) anti-HBs titre influences the number of revaccinations needed to reach a 
protective anti-HBs titre in hepatitis B non-responders. We evaluate the diagnostic 
performance and comparability of four commercial anti-HBs assays differentiating 
between titre height and the clinical applicability of differentiating between three 
or one doses revaccination schedules.
Chapter 6 describes a retrospective study that estimates the contribution of 
Sexual Health Centres (SHCs) in CHB case finding compared to the number of CHB 
notified patients in the Netherlands. We will use surveillance data from consultations 
from a nationwide network of SHCs to shed light on the contribution of SHCs in 
CHB case finding as well as the underlying characteristics of the chronically infected 
patients.
 Chapter 7 uses notification data from the Dutch Committee for Prevention of 
Iatrogenic Hepatitis B of healthcare workers with an infection of hepatitis B. We asses 
the longitudinal changes in viral load of hepatitis B virus–infected healthcare workers 
(HCWs) and its consequences for exclusion of infected HCWs performing exposure-
prone procedures.
Finally in chapter 8 we discuss the implications of the findings of the previous 
chapters on the prevention and control strategies to protect individuals or specific 
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Targeted vaccination strategies are necessary to prevent people who use drugs 
(PWUD) becoming infected with hepatitis B virus (HBV). The aims of this study were to 
provide an overview of the activities for PWUD in a decentralised vaccination program 
in the Netherlands and to explore the determinants associated with completing a 
standard hepatitis B vaccination series.
Methods
We used data for behavioural risk groups from the register of the national vaccination 
program. The data concerned PWUD who were immunised against hepatitis B in the 
Netherlands between 2002 and 2011. A standard series of three vaccinations (at 0, 
1, and 6 months) was offered at inclusion and was continued if serological markers 
for past or CHB infection were absent. Completion of a vaccination series ( at least 
three vaccinations, irrespective of timing) was a dependent variable in our logistic 
regression analysis.
Results
The program reached 18,054 PWUD. Of the 15,746 participants eligible for vaccination 
(i.e. they were neither carriers of hepatitis B nor immune to hepatitis B), 9089 (58%) 
completed a series of three hepatitis B vaccinations. Factors associated with a 
higher completion rate of a vaccination series (p<0.01) were: starting vaccination in 
the earlier years of the program, older age of PWUD, intravenous drug use, vaccine 
administration by addiction care centres, and flexibility in location of vaccine delivery.
Conclusion
Despite using a standard HBV vaccination schedule and no financial incentives, 
vaccination completion among PWUD was relatively high. Our results suggest 
that flexibility of vaccination location and administration of vaccines by healthcare 
workers with sustainable contact with PWUD could improve vaccination programs 
for this risk group.
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Introduction
Western industrialised countries have implemented several vaccination strategies 
against hepatitis B to reduce the incidence of acute and chronic infection with 
hepatitis B virus (HBV). Universal vaccination, vaccination targeting specific high-
risk groups, and a combination of both were strategies mostly implemented during 
the 1990 s.1,2 Only the four Scandinavian countries have not yet included universal 
hepatitis B vaccination in childhood vaccination programs. The immunological effects 
of childhood programs will take several decades to protect an adult population against 
HBV infection because not all countries have augmented childhood vaccination 
with a catch-up program for youth and adolescents.2-5 Incomplete coverage can 
limit the impact of starting targeted and universal vaccination programs ‘early’. HBV 
transmission is ongoing in high-risk groups in the United States and Germany despite 
the introduction of targeted and universal vaccination in the 1980 s and the period 
1990-1995.6,7 Consequently, targeted vaccination of adults at risk of HBV infection 
remains essential in many western countries to reduce further transmission.8,9 10
In low endemic countries, virus transmission of acute hepatitis B cases occurs 
mainly through sexual contact in groups with high-risk behaviour such as men 
who have sex with men (MSM) or through the re-use of needles or other objects 
contaminated with infected blood either in a healthcare setting or among people 
who inject drugs (PWID). The latter is the fourth leading cause of transmission and 
accounts for 11.3 % of the acute cases in the European Union and the European 
economic area.4,11 Despite strong regional differences, increasing evidence suggests 
that the prevalence of hepatitis B surface antigen (HBsAg) is considerably higher 
among PWID than in the general population. A recent German study reports a 
prevalence five times as great among PWID as in the general population.12,6,13 Among 
people who use drugs (PWUD), the risk of infection with HBV is not only limited to 
people who inject drugs. Non-injecting PWUD have an increased risk of HBV infection 
as well, primarily via high-risk sexual behaviour.14-18 Frequent co-infection in PWUD 
of HBV and HIV or HCV often results in more severe liver related morbidity.17 19 The 
increased seroprevalence and disease burden urges for better prevention strategies 
against hepatitis B in this high-risk group.
Due to the low prevalence of HBV in the Dutch general population, the 
Netherlands implemented after a two-year pilot period a vaccination strategy 
targeting hepatitis B in high-risk behavioural groups in 2002 prior to implementing a 
universal childhood vaccination program in 2011. Initially, four groups were targeted: 
MSM, PWUD, commercial sex workers and heterosexuals with multiple sexual 
contacts. In 2007, heterosexuals with multiple sexual contacts were excluded due to 
their low prevalence of HBV infection. By the end of 2011, the program also stopped 
targeting PWUD because of the low prevalence of past and CHB infection, no ongoing 





For this study we looked at PWUD in the targeted HBV-vaccination program. 
Participation of this high-risk group in vaccination programs can be poor because 
of possible debts, unstable housing situations, stigma related to drug use and 
hepatitis B1,22-24 and opportunities that various organisations have missed.6,25 Besides 
participation, as a measure of a program’s reach, factors associated with improving 
vaccination series completion are equally important to effectively protect a high-risk 
population against hepatitis B.
This study presents an overview of one decade of the activities for PWUD in 
the national HBV vaccination program for Dutch risk groups and reports on factors 
associated with completing a standard series of three vaccinations against HBV.
Methods
Study population and data collection
Recruiting organisations entered participant and vaccination data in a national 
web-based database using a structured questionnaire. We extracted data for this 
observational retrospective study from this web-based database where vaccination 
data were stored anonymously. The web-based design enabled all participating 
organisations to access these data, which facilitated completing vaccination series 
for participants at various organisations (such as prisons and addiction care facilities). 
A person was categorised in this database as PWUD depending on his/her reported 
behavioural risk (at least drug use) and the location of received vaccinations. People 
who used any of the following drugs were eligible for vaccination: heroin, base coke/
crack, cocaine, amphetamine or methadone regardless of the administration route (by 
injection and/or not). People using recreational drugs (e.g. ecstasy) were not eligible 
for hepatitis B vaccination in the program. If a person’s behavioural risk was restricted 
to drug use, he/she was categorised as PWUD irrespective the location of vaccination. 
Anyone with other behavioural risk factors besides drug use was categorised as a 
PWUD if he/she received vaccinations at a prison or addiction care facility. All PWUD 
who met these criteria were included for analysis if their first vaccination visit was 
registered between 1 January 2002 and 31 December 2011.
The common database provided information about the location and region of 
vaccination, number of hepatitis B vaccinations, hepatitis B serology (antibodies to 
hepatitis B core antigen (anti-HBc) and/or HBsAg), and baseline characteristics: age, 
gender, method of drug use and previous or current activities in commercial sex work.
Recruitment sites
Addiction care in the Netherlands is characterised by low threshold care ranging 
from detection of substance abuse to treatment and rehabilitation. All public health 
services (PHS) in the Netherlands cooperated regionally with addiction care facilities, 
homeless shelters and prisons to offer a standard series of hepatitis B vaccination 
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(0,1, and 6 months), free of charge at the locations mentioned. Local policy of 
organisations determined the extent of training of professionals for this program 
and cooperation between organisations. A yearly exchange of the program’s best 
practices was nationally organised for all participating organisations. Outreach 
activities (e.g. vaccination at methadone outlets or syringe exchange programs) were 
included in the program to inform and vaccinate participants, as well as to optimise 
the uptake. The participants who finished the vaccination series could receive an 
incentive (such as a pocket radio; no financial incentives were given) depending 
on organisation’s policy. For the aims of the study, the organisation responsible for 
administering vaccination was registered as the organisation of vaccine delivery. 
The location of vaccination was not necessarily a location of that same organisation. 
For example, a health worker from a PHS could administer a vaccine series at an 
addiction care facility.
Procedures
During the first visit, each participant received his/her first vaccination and health 
workers took a venous blood sample that was sent to a regional laboratory to assess 
the HBsAg and anti-HBc as serological markers of a possible hepatitis B infection. 
Evaluation of a serological profile of hepatitis B can be complex due to declining 
antibodies, false-positive results or an occult HBV infection.26 In short, no further 
vaccination was offered to a person who was positive to anti-HBc and HBsAg 
(classified as carrier of hepatitis B) or who was anti-HBc positive and HBsAg negative 
(classified as immune to hepatitis B). Carriers of hepatitis B were referred to standard 
health care for evaluation of the chronic hepatitis B infection. The main purpose 
of this public health program was to increase immunity to HBV in PWUD and to 
stop possible spill over to other risk groups. Therefore antibodies against HBsAg 
from individual participants were not routinely tested after vaccination to assess 
HBV immunity.
Ethical approval
The data were obtained from anonymous digital records in a fully de-identified 
manner and none of the researchers had access to patient identifying information. 
The study protocol was therefore exempt from formal medical-ethical approval under 
the prevailing Dutch laws because this is a retrospective observational study using 
anonymous data only.
Statistical analysis
The primary outcome was successful vaccination against hepatitis B, defined as 
completion of a series of at least three vaccinations, irrespective of the timing of 
the vaccine administration. Vaccination completion rates were computed only for 
PWUD participants eligible for further vaccination (HBV carrier and those immune 




expressed in months with an interquartile range (IQR). Participant characteristics per 
onset year of vaccination were compared using a t-test or chi-square test. We used 
logistic regression analyses with completion of a vaccination series as a dependent 
variable for calculating the odds ratio (OR) and 95%CI of the independent variables. 
Variables that were significantly associated with the outcome variable (vaccination 
completion) at the p 0.10 level in a bivariate analysis were entered in a multivariable 
analysis. A significance level of a p value <0.01 was considered significant in the 
multivariable analysis. We used SPSS version 22 (IBM, Armonk, NY, USA) for the 
statistical analyses.
Results
The program reached more than 18,000 people who use drugs. Table 1 shows their 
characteristics. Of the 18,054 participants, 2302 participants (12.8%) had positive 
anti-HBc blood tests. In this group, 134 persons had detectable HBsAg (5.8%; 0.7% 
overall). A total of 6.3 % of the participants reported that they had injected drugs in 
the past or last 6 months.
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Table 1. Characteristics of participants in the national vaccination program against hepatitis B virus in 
people who use drugs.
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Not eligible for further vaccination* 2308
Intravenous drug use (%)
 yes, in the past 802 (4.4)
 yes, last 6 months 327 (1.8)
  no (drug use, not IV) 16,925 (93.7)
Commercial sex work
 yes, in the past 1415 (7.8)
 yes, last 6 months 137 (0.8)
 No 16,500 (91.4)
 Unknown 2 (0.0)
*HBV carrier or immunity to hepatitis B. In addition to 134 HBsAg-positive and anti-HBc-positive participants 
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More than half of the participants (N=9592) started their vaccination series at the 
location of an addiction care facility. However, PHSs organised and administered most 
vaccination series (N=9410), followed by addiction care (N=5478) (table 2). A total of 
17,816 participants (98.7%) received their first vaccination. Of the 15,746 participants 
eligible for vaccination, 12,683 (80.5%) and 9089 (57.7%) received the second and 
third vaccinations, respectively. Only a minority (<100 participants) received more 
than three vaccinations.
The median time to completion was 7.1 months, (IQR 6.2 – 9.9) for a standard series. 
The vaccination completion rate gradually dropped from 74.7% in 2002–2003 to 41.3% 
in 2010–2011. The participants who started in 2002–2003 differed significantly from 
those who started in 2010–2011 in age, intravenous drug use, anti-HBc, and HBsAg 
serology. Over time the proportion of intravenous drug use (currently or in the past) 
declined from 12.9% to 3% (table 3).
Table 3. Characteristics and vaccination completion rate of PWUD participating in the national 
vaccination program against hepatitis B virus over time per two-year period (N = 18054)
Year starting vaccination series 2002–2003 2004–2005 2006–2007 2008–2009 2010–2011
N 2930 6069 4506 2707 1842
Gender male % 81.2 84.1 82.6 84.6 82.8
Age mean 37.6 37.0 37.2 36.6 38.7*
Anti-HBc %
  Yes 15.7 15.5 13.5 6.6 5.5*
  no 76.6 75.9 77.3 75.1 77.6
 unknown 7.7 8.6 9.2 18.3 16.9*
HBsAg %
  Yes 0.7 0.8 0.7 0.7 0.4
  No 14.7 14.5 12.5 5.6 4.8*
 Not tested, anti-HBc
 negative
84.6 84.8 86.8 93.7 94.8*
Intravenous drugs use %
 Yes, in the past 11.5 4.8 2.2 1.2 2.2*
  Yes, last 6 months 1.4 3.3 1.1 0.8 0.8
  No (drug use, not IV) 87.1 91.9 96.6 98.0 97.0*
Vaccination series
completed % 74.7 62.4 57.8 42.6 41.3*
*statistically significant difference compared to year 2002–2003 (p< 0.05)
Anti-HBc, antibody to hepatitis B core antigen; HBsAg, hepatitis B surface antigen
Factors associated with completion of a vaccination series
All the variables in univariate analyses were significantly associated with completion 




commercial sex work activities. In a multivariable logistic regression analysis the 
year starting a vaccination series, intravenous drug use, age, gender, and vaccination 
at different locations and organisation of vaccine delivery remained significantly 
associated with completion of the vaccination series (p<0.01, Table 4).
Table 4. Univariate (unadjusted) and multivariable logistic regression model for variables with completion 
of a vaccination series as outcome variable.
Univariate n=15,746 Multivariable n=11,891*
n p OR p OR 95%CI
Period 15,746 <.001 <.001
  2002-2003 2469 reference reference
  2004-2005 5129 <.001 0.56 <.001 0.68 0.59-0.77
  2006-2007 3895 <.001 0.47 <.001 0.65 0.57-0.75
  2008-2009 2522 <.001 0.25 <.001 0.40 0.34-0.47
  2010-2011 1731 <.001 0.24 <.001 0.37 0.31-0.44
Gender 15,746
  Female 2656 <.001 1.20  0.009 1.16 1.04-1.30
Intravenous drugs 15,746 <.001 <.001
 No 14,776 reference reference
  Yes, in the past 668 <.001 3.15 2.02 1.57-2.59
  Yes, in the last 6 months 302 <.001 2.57 2.06 1.45-2.91
Age (continuous) 15,746 <.001 1.02 <.001 1.02 1.02-1.03
Commercial sex work 15,746
 yes 1382  0.76 1.02 N.A. N.A.
Difference in location of
vaccine delivery
11,8911
 Different locations 2184 <.001 2.19 <.001 2.10 1.86-2.38
Organisation of vaccine delivery 15,746 <.001 <.001
  Regional public health service 8172 reference reference
  Addiction care facilities 4752  0.26 1.04 <.001 1.38 1.24-1.53
  Prison 2513 <.001 0.61 <.001 0.77 0.68-0.87
  Other 309 <.001 0.65  0.107 0.78 0.57-1.06
n=Number of participants eligible for vaccination (no hepatitis B carriers no immunity to hepatitis B)
1 Difference in ‘location of vaccine delivery’ was available for participants with data who received at least 2 
vaccinations given.
* Computed for 11,891 participants with data for all variables in the multivariable analysis
N.A. not applicable
35
Predictors of hepatitis B vaccination completion among people who use drugs
Discussion
The hepatitis B vaccination program targeting PWUD succeeded in involving various 
organisations whose outreach activities took place close to the living environment of 
this high-risk group. To our knowledge this is the largest cohort (18,054 participants) 
seen in a period of ten years. In this program, 87.2% of the participants were eligible 
for further vaccination and 57.7% completed a regular vaccination series.
Improving vaccination series completion
Our results from the multivariable analysis suggest that a higher completion rate 
for vaccination series was associated with starting vaccination in the earlier years 
of the program, an older age of PWUD, women, intravenous drug use, vaccine 
administration by addiction care centres, and flexibility in location of vaccine delivery. 
An effect consistent with earlier studies was vaccination completion being more 
likely in an older population.27,28 Additional efforts should therefore be made to 
encourage a younger population using drugs to complete a vaccination schedule. 
Vaccination completion was also more likely if addiction care facilities administered 
the vaccination series, instead of the PHSs. This result confirms previous research 
that shows that more participants informed by drug service staff of addiction care 
facilities were vaccinated than participants informed by PHSs or flyers. A personal, 
sustainable contact between drug service staff and PWUD, facilitated by familiarity 
with substance abuse problems and higher frequency of working with PWUD, might 
explain this difference.29-31 Vaccination completion was less likely if correctional 
facilities administered the vaccination series, rather than PHSs. This could be due 
to the many transfers of prisoners from prison to prison which results in a loss of 
vaccination information despite the use of a common database. A lost to follow up of 
people because of a shorter incarceration than the minimum time it takes to complete 
a standard series of hepatitis B vaccination is less likely as other organisations also 
have a lost to follow up for numerous reasons (such as moving house or stopping 
treatment). Moreover, the program facilitated completion of a vaccine series at a 
broad spectrum of organisations and locations that made it as convenient as possible 
to obtain a vaccination. Indeed, different locations of vaccination within a series were 
associated with better vaccine series completion. The multidisciplinary approach of 
this program, combined with a common database allowed flexibility in the location 
of vaccination regardless of the setting of first vaccination. This flexibility is likely to 
have improved the continuity of care for this highly mobile risk group.
In a Swedish study among PWID of whom 1142 initiated vaccination, a comparable 
59.2% completed the standard vaccination series.32 However, in our study the 
vaccination completion rates significantly decreased from 75% in the 1st year of the 
program to 41% in the final year. Participants in the earlier years of the program 
were probably more willing to be vaccinated and/or tested for HBV serology. The 




to reach PWUD in the final years of the program. This circumstance probably led to 
a lower completion rate and a higher proportion of participants with an unknown 
anti-HBc status.
Financial incentives and an accelerated vaccination schedule had also proved 
helpful in prior studies to improve vaccination completion rates in an unstable drug-
using population (vaccination completion between 31- and 83%).27,28,33-37 Compared 
to these studies we achieved a relatively high completion rate of 58% without 
any financial incentives or accelerated schedules. Offering earlier immunological 
protection in accelerated schedules (0,1, and 2 months) could also possibly prevent 
the HBV infection that is seen before completion of the intended standard schedule.32 
However, caution should be used with accelerated hepatitis B schedules because 
there is little validation of the long-term effectiveness of these alternative schedules 
in larger cohorts at high risk of hepatitis B. A booster dose is recommended after one 
year to improve long-term effectiveness in accelerated schedules.38 The program 
did not choose an accelerated vaccination schedule because of the expected poor 
compliance with the booster dose.
In our study injection drug use was positively associated with completing the 
vaccination schedule in the multivariable analyses. It is difficult to explain this 
association because the results for injection drug use are conflicting for completion 
of the hepatitis B vaccination schedule.39-41 In the program, self-reported past and/or 
current injection drug use decreased until 2005 and stabilised at about three percent 
from 2006- to 2011. In 2012, 1200 (8.6%) of the approximately 14,000 Dutch residents 
who were problematic opioid drug users, injected drugs, which corresponds to 0.11 
PWID/1000 people (aged 15-64 years). This is a strikingly low prevalence compared to 
recent estimates of less than 1 to more than 9 cases per 1000 people (aged 15-64 years) 
in other European countries.42-44 After 2002, an increase in immunisation coverage 
and referral to standard care of HBV carriers discovered in the program, could have 
altered further transmission dynamics of hepatitis B among PWUD. If indicated, 
antiviral agents can reduce infectivity by effectively reducing the viral load of HBV. 
Consequently, in 2012, the program no longer regarded PWUD, including PWID, as 
a risk group to be tackled in a national vaccination campaign against hepatitis B. 
An analysis confirmed that the program for PWUD was most cost-effective during 
the first half of the program (2002–2006) and was more expensive per protected 
individual in later years.45 In 2012, vaccination of PWUD was recommended to be 
part of specialist addiction care in the Netherlands. Unfortunately, there are several 
barriers to implement this policy, but there is progress, albeit slow. The current most 
important barriers are financial regulations and local policy issues.46
Limitations
We considered participants with anti-HBc to be immune to hepatitis B and therefore 
ineligible for further vaccination. However, immunity cannot be proven for a small 
proportion of people with ‘core-only’ antibodies against hepatitis B. 47 We may have 
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falsely excluded some participants from receiving further immunological protection 
against hepatitis B. This observation will probably not have affected our study results, 
but should be considered in future prevention programs to effectively protect this 
population.
We defined a successful vaccination series to be at least three vaccinations given 
to increase immunity among PWUD. In contrast to the general population, PWUD 
have a suboptimal immunological response after vaccination.48 An antibody titre 
below 10 IU/l against HBsAg is considered unprotective and necessitates additional 
booster vaccinations. Some participants might have remained unprotected from 
HBV after completion of a standard series. The additional cost and logistic effort 
versus the risk of infection and vaccine effectiveness should be considered before a 
decision is taken to include post-vaccination testing in a public health vaccination 
program against HBV.32,45,49
The web-based database of the program was not primarily developed for research 
purposes. Some misclassification (1–2%) did occur in the ‘location’ variable. This could 
easily be corrected because of the additional information registered. Although this 
had no effect on the main results of our regression analysis, we cannot completely 
exclude some additional misclassification in the database. Risk behaviour was 
self-reported in this study. Because these questions are about sensitive personal 
information such as sexual behaviour and drug use, some participants might have 
been reluctant to answer all these questions honestly. This could have led to an 
underestimation of the risks reported.
Conclusion
Convenience is key to improve uptake and completion of a hepatitis B vaccination 
schedule among PWUD.29,37,50 Despite using the standard vaccination schedule and no 
financial incentives, a relatively high completion rate of HBV vaccination was achieved 
for this risk-group. Our results suggest that convenience might consist of flexibility in 
the location of vaccination facilitated by the use of a common database. Further, the 
specific organisation that administers a vaccine series seems relevant for improving 
vaccination completion. These results inform public health services to optimise 
hepatitis B vaccination programs in countries with ongoing HBV transmission among 
people who use drugs.
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Table S1. Comparison of people who use/used intravenous drugs versus people who use drugs
Use/used IV drugs drugs (no IV drugs)
Total 1129 16925
Total eligible for vaccination (%) 970 (86) 14776 (87)
Age (SD) 38,7 (8,1) 37,2 (10,1)
Gender (% male) 914 (81) 14108 (83)
Anti-HBc positive (%) 159 ( 14) 2143 (13)
Anti-HBc no blood withdrawal (%) 131(12) 834 (5)
Anti-HBc unknown (%) 918 (5) 37 (3)
HBsAg positive (%) 5 (0,44) 129 (0,76)
Commercial sex work, yes (%) 145 (13) 1407 (8)
Ethnicity Dutch (%) 1012 (90) 12043 (71)
Organization of vaccine series (%)
 Addiction care 478 (42) 5000 (30)
  PHS 625 (55) 8785 (52)
 Prison 25 (2) 2748 (16)
  other 1 (0) 392 (2)
Difference in location of
vaccine delivery N= 11891
  Different locations (%) 175 (21) 2361 (22)
Series completion (%) 768 (79) 8320 (56)
IV, intravenous; PHS, public health service
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Table S2. time interval of vaccination series and completion percentage of the national vaccination 
program against hepatitis B virus in drug users (N = 15746)*







Time to completion (in months),
8786 8786 8786
  Mean (SD) 2.6 8.8 11.4 (11.9)
 Percentiles  25 1.0 5.1 6.2
 Median  50 1.2 5.8 7.1
   75 1.6 7.5 9.9
   90 3.7 14.5 21.0
Range (min.-max.) 0.1 – 103.4 0.1 – 108.2 1.0 – 109.9
Vaccination series completion N (%) N.A. N.A. 9088 (57,7)
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Post-vaccination testing after hepatitis B vaccination is indispensable to evaluate 
long-term immunological protection. Using a threshold level of antibodies against 
hepatitis B surface antigen (anti-HBs) to define serological protection, implies 
reproducible and valid measurements of different diagnostic assays.
Objectives
In this study we assess the performance of currently used anti-HBs assays.
Study design
In 2013, 45 laboratories participated in an external quality assessment program 
using pooled anti-HBs serum samples around the cutoff values 10 IU/l and 100 
IU/l. Laboratories used either Axsym (Abbott Laboratories), Architect (Abbott 
Laboratories), Access (Beckman-Coulter), ADVIA Centaur anti-HBs2 (Siemens 
Healthcare Diagnostics), Elecsys, Modular or Cobas (Roche Diagnostics) or Vidas Total 
Quick (Biomerieux) for anti-HBs titre quantification. We analysed covariance using 
mixed-model repeated measures. To assess sensitivity/specificity and agreement, 
a true positive or true negative result was defined as an anti-HBs titre respectively 
above or below the cutoff value by ≥ 4 of 6 assays.
Results
Different anti-HBs assays were associated with statistically significant (P < 0.05) 
differences in anti-HBs titres in all dilutions. Sensitivity and specificity ranged 
respectively from 64%-100% and 95%-100%. Agreement between assays around an 
anti-HBs titre cutoff value of 10 IU/l ranged from 93%-100% and was 44% for a cutoff 
value of 100 IU/l.
Conclusions
Around a cutoff value of 10 IU/l use of the Access assay may result in false-negative 
results. Concerning the cutoff value of 100 IU/l, a sample being classified below or 
above this cutoff relied heavily on the specific assay used, with both the Architect 
and the Access resulting in false-negative results.
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Background
The lack of global hepatitis B virus (HBV) vaccination coverage, the absence of 
sufficient protection in part of the vaccinees and the failure of protection in 10-30% 
of newborns from highly viremic mothers results in ongoing global transmission of 
hepatitis B.1,2 The cornerstone in prevention of hepatitis B infection and the long-term 
sequelae is immunisation.1 In 1983, a safe and effective vaccine was introduced, which 
uses hepatitis B-surface antigen to stimulate the production of protective antibodies. 
To date approximately 180 countries have adopted the WHO recommendation of 
universal childhood vaccination with global vaccination coverage in children of 
84%.3,4
The majority of healthy vaccinees develop a protective antibody response, 
defined by most countries as an anti-hepatitis B surface antigen (anti-HBs) titre 
of >10 IU/l, measured 1-3 months after last vaccination.5-7 Some countries apply 
an anti-HBs titre > 100 IU/l as indication of long-term protection.8,9 5–30% of 
immunocompetent adults fail to develop an anti-HBs titre exceeding 10 IU/l.10 Well-
known risk factors for non-response in healthy persons are obesity, advanced age, 
male gender, smoking, and genetic predisposition.11-13 Immunocompromised patients 
and patients with renal insufficiency are at increased risk of non-response as well.14 
Serological testing for protective immunity is not routinely performed. However, 
post-vaccination testing is strongly recommended for persons whose subsequent 
clinical management, including revaccination strategy or post-exposure prophylaxis, 
depends on knowledge of their immune status. This includes persons with an 
occupational or non-occupational (e.g. high risk sexual behavior) risk of HBV infection 
and for immunocompromised persons with an increased risk of severe hepatitis 
B.15-18 Additionally, this recommendation applies to persons at increased risk of the 
previously mentioned vaccination non-response against HBV.10
Different commercially available diagnostic assays are used to measure the anti-
HBs-titre. Since transmission risk-assessment and corresponding policy rely on specific 
anti-HBs cutoff values, standardisation of anti-HBs assays is of great importance. In 
most commercial automated assays a WHO International Standard is now used for 
calibration of the anti-HBs assay.19 The currently available assays should at least be 
able to accurately and reproducibly measure anti-HBs cutoff values of 10 or 100 IU/l. 
However, different studies in the past have raised doubts about this assumption.8,20
Objectives
In this study we aim to assess the performance of currently used and commercially 
available anti-HBs diagnostic assays using data from 45 laboratories participating in 





To achieve standardisation among laboratories in the industrialised world and to 
support the quality of measurement procedures, laboratories participate in external 
quality assurance (EQA) programs. Data for this study were obtained from the EQA 
program ‘anti-HBs screen’ organised by the Dutch Foundation for Quality Assessment 
in Medical Laboratories (SKML) during three different test rounds in 2013.
Test samples
One SKML laboratory prepared the different test samples for all laboratories and 
collected all test results of participating laboratories. Pooled anti-HBs serum 
originated from a mixture of various positive anti-HBs sera, most probably consisting 
of mixed serum from both vaccinees as well as patients infected with HBV. The 
negative samples were made by using pooled anti-HBs negative serum.
The serum pool was diluted to various dilutions that were distributed in various 
combinations in three different test rounds. These serial dilutions were split in 
identical test samples of which one was sent to each participating laboratory. Not 
every laboratory participated in each test round. We analysed the quantitative results 
of selected dilutions 1:512, 1:128, 1:64, 1:8 and 1:4 besides the negative sample for 
anti-HBs, which represented anti-HBs results around the cutoff values 10 IU/l and 
100 IU/l. The number of different anti-HBs assays per sample dilution are provided 
in Supplementary Table 1. This resulted in a total of 494 anti-HBs measurements. 
Sample results were collected in a coded manner and outcomes were reported in 
a standardised manner (IU/l). An anti-HBs result that was not quantified around the 
lower limit of detection, was arbitrarily assigned a value half of the lower limit of 
detection (e.g. anti-HBs < 10 IU/l was recoded to an anti-HBs titre of 5 IU/l). According 
to Dutch legislation this study did not need an ethics approval.
Anti-HBs assay systems
45 laboratories (37 Dutch and 8 participants from outside the Netherlands) 
participated in the EQA program. Excluded were those laboratories that did not specify 
the manufacturer or test method used (two laboratories) or used an assay not in use 
in any other laboratory (Enzygnost, Dutch laboratory). We included 42 laboratories 
and the participating laboratories used either Axsym (Abbott Laboratories), Architect 
(Abbott Laboratories), Access (Beckman-Coulter), ADVIA Centaur anti-HBs2 (Siemens 
Healthcare Diagnostics), or Vidas Total Quick (Biomerieux) assay system for anti-HBs 
titre quantification (Table 1). One of the following three assays from Roche Diagnostics 
was used without separate registration; Elecsys, Modular or Cobas. However as all 
assays from Roche diagnostics used a same kit applicable to these assays (Anti-HBs), 
results were taken together in further analysis. 38 laboratories made use of one and 
4 laboratories of two assays to determine anti-HBs titres.
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Statistical analysis
Primary outcome measure was the anti-HBs titre. The mean anti-HBs titre and the 
coefficient of variation (CV) were calculated for each sample separately. The CV was 
excluded for the negative sample as this is based on a mean titre close to zero and 
therefore less meaningful.
Analysis of covariance using mixed-model repeated measures with test round and 
test method (assay) as fixed effects was carried out to assess quantitative differences 
between test methods. Using the mixed-model (random intercept with two levels; 
measurements within specific test methods), we were able to take together results 
from the same dilutions from different rounds, thereby increasing our number of 
results.
For the assessment of agreement and sensitivity/specificity a true positive or true 
negative result was defined as an anti-HBs titre respectively above or below the cutoff 
value by ≥ 4 of 6 assays. Performance of anti-HBs results are presented in each dilution 
as a percentage agreement of assays compared to the true positive or negative value.
Statistical analysis was performed using SPSS version 22 (IBM Corp; Armonk, NY, USA).
Results
Results of the serial dilutions from the pooled sera for different assay systems are 
shown in figures 1 and 2. Mean anti-HBs results are shown for each sample by 
different assay systems. The Access assay reported anti-HBs titres below <10 IU/l for 
dilution 1:64 sample, while all five other assays had results above the cutoff (figure 
1).Sensitivity and specificity ranged respectively from 64% - 100% and 95% - 100% 
(Table 2).
Table 1. Source and type of antigen used as a reagent (human / recombinant) in anti-HBs assays
Anti-HBs assay* Antigen No. of 
laboratories‡/ 
no. of assays
Access (Beckman-Coulter) Human (ad / ay) 3 / 3
ADVIA Centaur
(Siemens Healthcare Diagnostics)
Human (ad / ay) 3 / 3
Elecsys –Cobas –Modular 
(Roche Diagnostics)
Human (ad / ay) 10 / 10
Architect (Abbott Laboratories) Recombinant; E. coli (ad / ay) 20 / 22
AxSYM (Abbott Laboratories) Recombinant; L. mouse cell (ad / ay) 6 / 6
Vidas (Biomerieux ) Inactivated plasma (ad) and recombinant (ay) 2 / 2
 * all assays were calibrated against the 1st International Reference Preparation WHO 1977





Figure 1. Mean anti-HBs results (95% CI) of different dilutions repeatedly analysed with different test 
methods
Table 2. Sensitivity and specificity calculated for different assays compared to an anti-HBs titre cutoff 
of 10 IU/l and 100 IU/l
Test assay Sensitivity % (a) Specificity % (b)
10 IU/l 100IU/l 10 IU/l 100 IU/l
Architect 99 (1/94) 69 (18/58) 100 (0/133) 100 (0/169)
Vidas 100 (0/10) 100 (0/6) 100 (0/14) 100 (0/18)
ADVIA Centaur 100 (0/15) 100 (0/9) 95 (1/21) 100 (0/27)
Roche 100 (0/48) 100 (0/28) 100 (0/68) 100 (0/88)
AxSYM 100 (0/23) 93 (1/14) 100 (0/33) 100 (0/42)
Access 64 (5/14) 67 (3/9) 100 (0/21) 100 (0/26)
 a 100 – (No. false-negative / total no. of true positive samples (at least 4 of 6 assays
anti-HB ≥ 10IU/l or ≥ 100IU/l)) x 100
 b 100 – (No. false-positive / total no. of true negative samples (at least 4 of 6 assays
 anti-HBs < 10IU/l or <100 IU/l)) x 100
Percentage agreement of each assay compared to the true negative value (negative 
sample, dilution 1:512 and 1:128) and the true positive value (dilution 1:64) with an 
anti-HBs titre cutoff ≥10 IU/l resulted in respectively 100%, 100%, 99% and 93%. In 
dilution 1:8 the percentage agreement compared to the true positive value with an 
anti-HBs titre cutoff ≥100(IU/l) dropped to 44% (Supplementary Table 2). Agreement 
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within an assay was remarkably consistent for this sample, except for AxSYM (Table 
3). Agreement compared to the true positive value for all assays was met for the 1:4 
sample.
Table 3. Number of assays providing results in categories of anti-HBs titres based on cutoff value of 100 
(IU/l) with dilution 1:8 (N = 39)
Test assay 1-9 (IU/l) ≥10-99 (IU/l) ≥100 (IU/l) Agreementa
Architect - 18 0 0%
Vidas - 0 2 100%
ADVIA Centaur - 0 3 100%
Roche - 0 9 100%
AxSYM - 1 3 75%
Access - 3 0 0%
 a percentage agreement compared to the true positive value in sample 1:8 with
 an anti-HBs titre cutoff ≥100 (IU/l)
Table 4 shows the mean anti-HBs titres from all serological assays for each of the six 
different dilutions. The coefficient of variation (CV) ranged from 57% to 17%. The CV 
was in general lower in less diluted samples (i.e. 1:4, 1:8 and 1:64) with consequently 
higher anti-HBs titres. In our mixed model only ‘test method’ was statistically 
significant (P <0.05) on the outcome of anti-HBs titre. Adding a third level ‘laboratory’ 
next to specific test method and measurements in our mixed model did not have an 




Figure 2. Mean anti-HBs results (95% CI) of diluted sample 1:4 and 1:8 repeatedly analysed with different 
test methods
Table 4. Descriptive statistics of all anti-HBs results per dilution and results of mixed-model repeated 
measures with test round and test method as fixed effects (N=496)







Fixed effect P- value
test method test round
Negative 123 1.1 (1.5) 0.0 – 5.0  - <0.05 0.60
1:512 83 2.1 (1.2) 0.0 – 5.0 57% <0.05 0.69
1:128 84 6.4 (1.9) 0.0 – 10.8 30% <0.05 0.81
1:64 80 13.2 (2.3) 6.0 – 18.1 17% <0.05 0.19
1:8 39 98.4 (17.5) 71.0 – 126 17% n.a.* n.a.
1:4 85 192 (37.7) 127 – 263 20% <0.05 0.58
SD: standard deviation. Range: Range of anti-HBs measurements are minimum and maximum values
* n.a.: not applicable, measurements available of one test round and therefore not suitable for a
 mixed model
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Discussion
To achieve standardisation among laboratories and to support the quality of 
measurement procedures laboratories participate in external quality assurance (EQA) 
programs. Results of EQA ‘anti-HBs screen’ used in this study confirm quantitative 
differences between assays as previously have been described.8,20-25 The mean 
coefficient of variation (CV) was 28% (range 17% –57%) and lower than the CV of 
another study comparing nine anti-HBs assays with a mean CV of 47.1% (range 
15%–201%).8 An explanation for the difference in CV could be the more diverse anti-
HBs samples originating from individuals instead of pooled serum samples. In our 
study pooled samples probably consisted of a mixture of antibodies originating 
from vaccinees and infected HBV patients. Huzly et al concluded that anti-HBs 
levels determined by one assay cannot be compared with those by other systems. 
Results from our mixed model confirmed that a different test method was statistically 
significant as a variable to explain differences in anti-HBs titres.
Quantitative differences between test assays will be inevitable to some extent. 
More important are differences in performance in relation to clinically relevant cutoff 
values, being that of 10 IU/l as a correlate of protection and that of 100 IU/l as a 
differentiator for risk of chronic, contagious, hepatitis B virus (HBV).26 Dilutions around 
the cutoff value of 10 IU/l (i.e. 1:64 and 1:128) showed solely in the 1:64 dilution a 
percentage agreement lower than 95%. The Access assay reported anti-HBs titres 
below 10 IU/l in the 1:64 dilution, compared to five other assays that had results 
above the cutoff value. These Access results may be regarded as false-negative 
taking the other assay results into account. A study in 2002 reported samples from 
Engerix-B vaccinees with anti-HBs levels up to 150 IU/l in AxSYM and Architect assays 
to appear sometimes negative in Access.20 In a direct comparison between Access 
and AxSYM assays of 1207 samples, 51 (4.2%) samples were discrepant and of 369 
true positive samples, 8 samples (2%) remained false-negative by Access assay after 
retesting.24 A false-negative outcome may result in unease concerning an erroneous 
lack of immunity against HBV, additional testing to rule out a HBV infection and 
unnecessary revaccination. Luckily a possible false-negative result is less harmful 
than a false-positive outcome, as the superfluously administration of vaccination or 
administration of immunoglobulins is less potentially harmful than falsely refraining 
of additional protective measurements against HBV. A false-positive anti-HBs result 
is worrisome as this may result in clinically apparent HBV infection or CHB infection. 
Fortunately clinically important breakthrough HBV infections after vaccination are 
rare and mainly described in case reports and point to primary vaccine failure (anti-
HBs < 10 IU/l), escape-mutant HBV strains and waning immunity as explanations of 
infection.27-29
Differences of the anti-HBs assays have led to the advice of Huzly et al. to raise the 
current cutoff values in order to prevent false-positive outcomes.8 Several national 




this recommendation, maintaining the cutoff value for complete protection at 100 
IU/l.15, 16 Hardly any false-positive results were seen in our data. However, the use of 
pooled serum samples instead of individual samples may have led to less diverse 
anti-HBs results. In other countries this elevated cutoff is only applied in a specific 
group of healthcare workers (HCWs) with an occupational risk of hepatitis B, that are 
also at risk of transmitting HBV to patients during the performance of exposure prone 
procedures. The anti-HBs titre cutoff is raised for these HCWs to ≥ 100 IU/l to minimise 
risks of erroneously suggesting immunity with absence of HBV infection. Above this 
cutoff the risk of a HCW with concurrence of anti-HBs antibodies and a HBV carrier 
state is minimal.26,30 Concerning this second cutoff value the performance of the 
different assays could be compared using the 1:8 sample which had a mean anti-HBs 
titre of 98.4 (IU/l). In this sample the agreement was 44% between different assays. 
A sample being classified below or above this cutoff relied heavily on the specific 
assay used, with both the Architect and the Access resulting in false-negative results.
Various authors have offered possible explanations for differences in anti-HBs 
titres between assays, for example differences in vaccine antigens used to elicit 
antibodies against HBsAg, diversity of individual immune response, interference 
with other substances or a matrix effect.20-24 In our study, samples were derived from 
pooled serum, which may not be fully comparable to single human sera. On the 
other hand, because the composition, the matrix and possible interfering substances 
in the samples are the same, the assays may be compared. It is however possible 
that different types of assays react differently on the same matrixes or substances. 
Use of a different International Standard for hepatitis B immunoglobulin may have 
a minor influence on anti-HBs results.19 As all assays were calibrated against the 1st 
International Reference Preparation this cannot explain any differences in anti-HBs 
results.
A final explanation for differences between assays could be the differences in 
HBsAg antigen, serotype and source, used as a test reagent.21 One study concluded 
that discrepancies between assays were depending on the combination of antigen 
in vaccine and antigen in the assay used.20 However, two more recent studies do 
not support this hypothesis, since assays using the same antigen still showed large 
discrepancies and minimal differences existed with assays using different antigens.8,19 
Indeed, results by Access were below a cutoff titre of 10 IU/l and 100 IU/l in respectively 
dilution 1:64 and 1:8, whereas results by ADVIA Centaur and Roche were above the 
cutoff, all using the same HBsAg antigen (ad ay) from human origin (Table 1). However, 
one cannot rule out that a different antigen production, purity and concentration 
could possibly explain differences in anti-HBs results.
Detailed information was lacking on the origin of the pooled serum samples, 
probably consisting of a mixture of antibodies originating from vaccinees and 
infected HBV patients. Consequently this limits the external validity of our results to 
a specific situation of measuring antibodies against HBsAg after vaccination or HBV 
infection. In future research it is preferable to test assays from a known serum pool 
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or from individual blood donations collected after vaccination with a recombinant 
vaccine or collected after HBV infection. Anti-HBcore status of samples (positive or 
negative ) did however not influence the CV of anti-HBs titres in a previous study.8
In earlier studies, detailed information was lacking on the number of assays that were 
compared within a laboratory. If only one laboratory per type of assay was used, it 
leaves the possibility that differences did not result from differences between assays 
but from differences between laboratories. Adding laboratories as another level in 
our mixed model did not change our results, which indicates that the influence of a 
specific laboratory on anti-HBs results is negligible. However because of the small 
number of four laboratories testing samples with more than one assay, we may not 
have been able to detect a possible difference.
This study confirms an influence of different anti-HBs assay systems on 
quantification of anti-HBs titres around clinically important cutoff values. Concerning 
the cutoff value 10 IU/l use of the Access assay may result in false-negative results. 
Around a cutoff value of 100 IU/l, a sample being classified below or above this cutoff 
relied heavily on the specific assay used, with both the Architect and the Access 
resulting in false-negative results.
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Diagnostic performance of serological assays for anti-HBs testing
Table S2. Number of assays per dilution providing results in categories of anti-HBs titres based on cutoff 
values of 10 (IU/l) and 100 (IU/l) with the corresponding percentage agreement.
Sample 1-9 (IU/l) ≥10 -99 (IU/l) ≥100 (IU/l) Agreement*
Negative 123 0 - 100%
1:512 83 0 - 100%
1:128 83 1 - 99%
1:64 6 74 - 93%
1:8 - 22 17 44%ǂ
1:4 - 0 85 100%ǂ
*percentage agreement compared to the true positive or negative value in sample negative, 1:512, 1:128 and 
1:64 with an anti-HBs titre cutoff of 10 (IU/l)
ǂ percentage agreement compared to the true positive or negative value in sample 1:8 and 1:4 with an anti-
HBs titre cutoff ≥100(IU/l) 3
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Serological non-response can be present after hepatitis B vaccination in healthy 
adults. We aimed to establish which of three revaccination regimens is most effective 
at inducing protective immunity.
Methods
Healthy adults (aged 18–80 years) from 16 Dutch centres (13 public health services, 
two university hospitals, and one travel clinic) were included in this multicentre, 
parallel group, randomised, controlled, superiority trial. The inclusion criterion was 
vaccine non-response (hepatitis B surface antibody [anti-HBs] titre <10 IU/L) after a 
primary series with three doses of one type of recombinant vaccine against hepatitis 
B virus (either HBVaxPro-10 or Engerix-B at months 0, 1, and 6). Participants were 
individually randomly assigned (1:1:1:1) to a vaccination series of repeated initial 
vaccination (HBVaxPro 10 µg or Engerix-B 20 µg) as the control, or to Twinrix 20 µg, 
Fendrix 20 µg, or HBVaxPro 40 µg. We used a web-based randomisation programme, 
stratified by centre, with a block size of four. Participants and centres were unmasked 
to assignment after randomisation. Laboratory staff and investigators were masked 
to vaccine-group assignment. All revaccination schedules were identical, with 
intramuscular vaccinations at 0, 1, and 2 months. Anti-HBs was measured at 0, 1, 2, 
and 3 months. The primary outcome was the percentage of responders (anti-HBs 
titres ≥10 IU/L) at 3 months. Immunogenicity and safety analyses were based on an 
intention-to-vaccinate analysis, the immunogenicity analysis with last observation 
carried forward for missing data, and the Bonferroni and the Benjamini–Hochberg 
method were applied to correct for multiple testing. The trial was registered in the 
Dutch National Trial Register and inclusion has been stopped (identifier NL3011; 
EudraCT-number 2011-005627-40).
Findings
The participants were recruited between Nov 1, 2012, and Sept 1, 2017. 480 participants 
were randomly assigned and included in intention-to-vaccinate analyses: 124 (26%) 
to control, 118 (25%) to Twinrix, 114 (24%) to HBVaxPro-40, and 124 (26%) to Fendrix. 
At month 3 the percentage of responders was 83 (67%) of 124 (95% CI 57·9–75·1 in the 
control group, 94 (80%) of the 118 (71·3–86·5) in the Twinrix group, 95 (83%) of 114 
(75·2–89·7) in the HBVaxPro-40 group, and 108 (87%) of 124 (79·9–92·4) in the Fendrix 
group. Compared with the control group, the percentage of responders was superior 
for the HBVaxPro-40 group (adjusted difference 21·6% [95% CI 10·4–32·7], p=0·0204 
[Bonferroni corrected p value]) and the Fendrix group (26·3% [15·4–37·3], p=0·0006), 
but not the Twinrix group (25·0% [13·0–37·0]; p=0·0846). One serious adverse event 
occurred (herpes zoster ophthalmicus) in the Fendrix group, which was not attributed 
to the vaccine.
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Interpretation
Revaccinating healthy non-responders with Fendrix or HBVaxPro-40 resulted in 
significantly higher proportions of responders and therefore indication for these 
vaccines should be expanded to enable revaccination of non-responders.
Funding





A safe recombinant vaccine against hepatitis B virus (HBV) has been available 
since 1986. The introduction of this vaccine in universal childhood vaccination and 
programmes targeting specific high-risk groups has reduced the rate of acute and 
chronic hepatitis B (CHB) infections and their sequelae (eg, cirrhosis and hepatocellular 
carcinoma) in many countries.1 Owing to the low estimated prevalence of CHB 
infection of 0·2% in the general Dutch population, the Netherlands implemented a 
vaccination strategy targeted at high-risk groups for hepatitis B since 2002, before 
implementing universal childhood vaccination in 2011.2 Adult risk groups still have to 
be vaccinated to reduce transmission of HBV as it takes decades for vaccinated birth 
cohorts to reach adulthood and intervene in adult risk groups. Most healthy adults 
develop a protective antibody response, defined as an antibody titre (anti-HBs) of 10 
IU/l or more against hepatitis B surface antigen (HBsAg), measured 1 to 3 months after 
the last vaccination.3 However, 5 up to 30% of healthy vaccine recipients (depending 
on age) develop anti-HBs serum concentrations of less than 10 IU/l and are defined 
as non-responders.4-6
Non-responsiveness to the vaccine not only has major implications for individuals 
at high risk of hepatitis B (eg, healthcare workers and sexual partners of carriers of 
HBV), but it also hampers a possible rapid global eradication of HBV. Well-known 
risk factors for non-response in healthy people are male sex, increasing age, obesity, 
smoking, genetic predisposition and the subcutaneous route of administration of 
the vaccine.4,5,7 The exact immunological mechanisms of non-response have not 
yet been elucidated.8 Guidelines recommend revaccinating non-responders with 
additional vaccine doses. Dutch guidelines recommend three revaccinations of a 
standard vaccine administered at months 0, 1, and 2 which induces a seroconversion 
rate of 50 to 70%.9,10 In a proof-of-principle trial, increasing the cumulative antigen 
dose achieved by increasing the number of administered doses of a standard vaccine, 
all the participants eventually reached antibody concentrations greater than 10 IU/l.11 
Additional strategies to increase the immune response in healthy non-responders are 
vaccination with higher doses of HBsAg, combining HBsAg with other antigens, and 
use of more potent adjuvants or alternative routes of administration.5 7,12-17 A meta-
analysis comparing revaccination regimens by dosage and route of administration 
suggests a higher seroconversion rate after the first additional dose, regardless of 
the revaccination regimen chosen 17 This growing body of evidence strengthens the 
expectations that alternative vaccine schedules will overcome non-responsiveness. 
However, these trials generally had small sample sizes, deviating vaccine dosages 
or vaccination intervals, or retrospective study designs, or both, and did not all 
report on antibody titres in non-responders.13-15 17 This is important as the nearly 
complete absence of an anti-HBs titre is associated with lower seroconversion rates 
after revaccination than an anti-HBs titre above the cutoff limit of detection.5,10 In 
some studies, the interval between final vaccine dose and anti-HBs testing was more 
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than 6 months or unknown, the number of previous vaccinations was variable, or a 
vaccine had been used that was withdrawn from the market.5,18,19 We have done the 
current trial to overcome these limitations. The aim of this study was to establish the 
immunogenicity in hepatitis B non-responders of a three-dose revaccination series 
at a 4 weeks interval with (Twinrix, Fendrix or HBVaxPro-40) compared to a standard 
revaccination series of three Engerix-B (with 20 μg HBsAg) or HBVaxPro-10 (with 10 
μg HBsAg).
Methods
Study design and participants
We did a randomised, open-label, parallel group, controlled, multicentre superiority 
trial. The study centres were 13 public health services, two university hospitals, and 
one travel clinic in the Netherlands. Written informed consent was obtained from 
each participant before study enrolment. The inclusion criterion was vaccine non-
response after one initial standard series of three HBV vaccinations at months 0, 
1, and 6, with either HBVaxPro-10 or Engerix-B, as both vaccines have no clinically 
significant differences in immunogenicity.20,21 Non-response was defined as an anti-
HBs titre of less than 10 IU/L, measured in serum 4 weeks to 3 months after the 
last vaccination and assessed according to the local laboratory serology standard. 
All anti-HBs assays from laboratories were commercially available, and externally 
and internally validated. The additional inclusion criteria were age 18–80 years and 
administration of recombinant HBV vaccine from one manufacturer in the initial 
series. Accepted minimum intervals between the first dose and second dose were 3 
weeks; between second dose and third dose, 2 months; and between the first dose 
and third dose, 4 months.
Exclusion criteria were self-reported immune-incompetence (due to 
immunosuppressive medication or disease, or both), deviations from the number of 
vaccinations of the standard series based on medical records of participating centres, 
and an initial series given more than 12 months before inclusion. Participants were 
questioned about the use of any medication before enrolment and 7 days after each 
revaccination, to decide whether that could negatively affect the immune system. 
If the local researcher was in doubt about the use of medication and the exclusion 
criteria, he or she discussed this with the coordinating researcher who could consult 
a medical specialist in internal medicine for the final decision. To rule out chronic or 
hidden HBV infection as a cause of vaccine non-response and to exclude people with 
a previous HBV infection, seropositivity for HBsAg or antibodies to anti-HBc based on 
laboratory tests were also an exclusion criterion. The Dutch Central Committee on 
Research Involving Human Subjects (CCMO, NL36395.058.12) and the Medical Ethics 





Figure 1. trial profile
*Based on estimates from centres who provided a third of the participants
Randomisation and masking
Participants were individually randomly assigned in this open-label trial with an 
allocation ratio of 1:1:1:1 to one of the following groups: repeating initial series 
for the control group (HBVaxPro 10 μg or Engerix-B 20 μg), a combined vaccine 
against hepatitis A and hepatitis B (Twinrix 20 μg), a vaccine with an AS04 adjuvant 
containing 3ʹ-deacylated monophosphoryl lipid A and aluminium salt (Fendrix 20 
μg), or a vaccine with a higher antigen dose (HBVaxPro 40 μg). Fendrix and HBVaxPro 
are registered for use in patients with end-stage renal disease. We used a central 
web-based randomisation programme for allocation to one of the vaccine-groups, 
stratified by site with a fixed block size of four. After the participant’s informed 
consent was obtained, a staff-member of that centre uploaded a limited patient-
specific dataset in the randomisation programme that enabled the allocation to 
one of the vaccine groups. Participants and staff of the participating centres were 
unmasked to assignment after randomisation. The central laboratory staff (LUMC) 
who analysed the samples were masked to vaccine-group assignment. Investigators 
were masked to assignment for analysing data and assessing outcomes of the study.
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Procedures
After enrolment, we collected data about age, sex, body-mass index, smoking 
habits, country of birth, general information on medical conditions, and primary 
vaccination schedule. Furthermore, data for timing between vaccinations and the 
interval between last vaccination and post-vaccination antibody concentrations were 
collected. These data were provided by participating centres originating from their 
medical records. All revaccination schedules were identical according to professional 
standards with a single intramuscular dose administered in the deltoid region at 
months 0, 1, and 2. The minimum interval allowed between vaccinations was 3 weeks. 
One venous blood sample was taken at months 0, 1, and 2 and two blood samples 
were taken at month 3 for anti-HBs titres. The interval between the final vaccination 
and anti-HBs serology was between 4 weeks and 3 months. Serum samples were sent 
to a central laboratory (LUMC) and stored at −20°C until the study was completed. 
After the final participant had been included, the samples were analysed for anti-HBs 
with the ARCHITECT analyser (Abbott Laboratories; Chicago, IL, USA) according to the 
manufacturer’s instructions. Anti-HBs values greater than 1000 IU/L were given the 
value of 1000 IU/L. The lower limit of detection of the assay was 0·98 IU/L. All values 
below the lower limit of detection were given a value of 0·49 IU/L. This enabled a 
transformation of anti-HBs titres to a log10 for computing the geometric mean titre for 
anti-HBs values of 0 IU/L. For timely patient information, one of two blood samples 
taken at month 3 was sent for anti-HBs testing to the local laboratory of each study 
site.
The participants were asked to note any possible injection site reactions or systemic 
symptoms in a diary during the week after vaccination. The diary card consisted of 
three items regarding a local reaction after vaccination (pain, erythema, and oedema), 
two items for systemic reactions (fever and myalgia), and free text fields for other 
possible reactions. The participants classified the severity of the local and general 
reactions on a four-point scale (absent–mild–moderate–severe).
Outcomes
As an anti-HBs titre of 10 IU/L or more is a correlate of protection against clinically 
relevant hepatitis B infections, our primary endpoint was the proportion of responders 
with an anti-HBs titre of 10 IU/L or more, 4 weeks to 3 months after completion of 
the revaccination series given at months 0, 1, and 2. Unlike the prespecified study 
protocol outcomes, we considered the geometric mean titres of anti-HBs measured 
at 1, 2, and 3 months to be a secondary outcome. Additional secondary endpoints 
were the number of revaccinations needed to reach serological response (anti-HBs 
≥10 IU/L) at 1, 2, and 3 months, proportion of responders 4 weeks to 3 months after 
completion of the revaccination series according to anti-HBs concentrations at 
baseline (<1 [zero responders] vs ≥1 to <10 IU/L [poor responders]),10 and all adverse 





We calculated the sample size on the basis of the expected difference of 15% between 
responders in the control group (70%) and the experimental group (85%) on the basis 
of previous literature and we did not apply a continuity correction.5,9,14-16 To attain a 
power of 80% at a type 1 error rate of 5%, we needed 120 participants in each group, 
resulting in 480 participants in total. The primary analysis of this superiority trial was 
an intention-to-treat analysis with the last observation carried forward (LOCF) for 
participants with any missing anti-HBs titre measurements. The intention-to-treat 
analysis with LOCF was added to the trial protocol after trial commencement. As 
the intention-to-treat principle might have a conservative effect on the outcome, 
it is considered the appropriate approach for superiority trials. The results of the 
per-protocol analysis in which participants vaccinated according to protocol were 
included is in the appendix.
Anti-HBs titres were visualised in a reverse cumulative distribution curve. The 
proportion of responders (anti-HBs ≥10 IU/L) in each vaccination group was calculated. 
The outcome variable (anti-HBs titre) was transformed to a log 10 variable to compute 
the geometric mean titre. Its sample mean per study group was back-transformed 
to express the geometric mean titre and 95% CI in terms of anti-HBs titres, which, 
at least in an approximate sense, refer to the median anti-HBs titres. Geometric 
mean titre ratios were calculated to express differences in geometric mean titres 
between vaccine groups. We used the permutation version of the test based on the 
so-called sum statistic to compare differences between vaccine groups regarding the 
proportion of responders and geometric mean titres.22 The sum statistic is equivalent 
to the Mantel–Haenszel test for a binary—our primary—outcome; it can be seen as 
a generalisation of Fisher’s exact test for the situation in which the various pairs of 
samples come from different strata or blocks (the centres in our case). In the case of 
a continuous outcome (our secondary outcome), the sum statistic is the sum of the 
within-stratum differences between average responses in the two vaccine groups 
being compared. To estimate the p values we have used 1 million permutations. The 
Bonferroni method was used to correct for multiple testing separately for the two 
endpoints; in each case, the probability of at least one type 1 error among a set of 
three tests was kept at 0·05. The results of the tests are accompanied by estimates 
of mean differences between treatment groups in order to quantify the magnitude 
of the effects of the vaccines. Each estimate is obtained as an average of differences 
between the average outcomes of the two groups being compared; the average 
of differences being taken over all the centres in which each group has at least 
two participants. The corresponding approximate 95% CI is based on the normal 
approximation and on the estimation of the variance of the parameter in terms of 
the within-centre variance estimates. The detection of differences between the four 
vaccine groups regarding adverse events was based on the generalised Cochran–
Mantel–Haenszel test (a generalised form of the χ2 test of homogeneity that combines 
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data from different blocks), with exact p values estimated by simulation followed 
by an application of the Benjamini–Hochberg method at a nominal false discovery 
rate of 10%.
We used SPSS 25.0 software and GraphPad Prism 5.03 software and the statistical 
tests were carried out with the R package coin.23 No data monitoring committee was 
used. The trial was registered in the Dutch National Trial Register and inclusion has 
been stopped (identifier NL3011); EudraCT-number 2011-005627-40).
Role of the funding source
The funders of the study had no role in study design, data collection, data analysis, 
data interpretation, or writing of the report. The corresponding author had full 
access to all the study data except identifying patient information and had the 
final responsibility for the decision to submit for publication. GlaxoSmithKline and 
Merck Sharp & Dohme provided the vaccines for this study. Neither manufacturer 
was involved in the study design, data collection, data analysis, interpretation of the 
results, or writing of the report.
Results
Between 1 Nov 2012, and 1 Sept 2017, of 640 patients screened for eligibility, 480 
were randomly assigned to one of the study groups (figure 1). In the primary HBV 
vaccination series, 104 of the participants were vaccinated with HBVaxPro-10, 373 
participants with Engerix-B, and three with Twinrix. These three participants violated 
the inclusion criteria and were excluded from the study and nine of the participants 
withdrew consent. Thus, 468 participants started revaccination in one of the four 
study groups (figure 1). Nine participants subsequently discontinued vaccination, of 
whom six withdrew consent, one left after a protocol violation, and two left after a 
violation of the inclusion criteria. The final blood samples of seven participants were 
missing in the group of 22 participants with missing blood samples.
The rates of completion of the full vaccination series were high and similar in all 
groups, ranging from 117 (94%) of 124 participants assigned to the control group to 













Age, years 45·3 (14·4) 44·8(14·2) 46·1 (15·9) 45·6 (13·3)
Sex, male 76 (61%) 56 (48%) 71 (62%) 65 (52%)
Active smoking* 31 (27%) 40 (36%) 31 (30%) 30 (25%)
BMI,kg m-2ǂ 26·4 (5·0) 27·2 (5·1) 26·4 (5·0) 26·7 (5·5)
Diabetes § 5 (4%) 7 (6%) 7 (7%) 8 (7%)
Baseline anti-HBs Titre <1 IU/l 54 (44%) 53 (45%) 50 (44%) 62 (50%)
Data are numbers (%) or mean (SD). Anti-HBs = antibodies against hepatitis B surface antigen
*Defined as smoking at least five cigarettes per day. Missing information in 11 (control), seven (Twinrix), nine 
(HBVaxPro-40), and six (Fendrix group) participants.
ǂMissing information in 13 (control), seven (Twinrix), 11(HBVaxPro-40), and six (Fendrix group) 
participants.
§Missing information in six (control), six (Twinrix), eight (HBVaxPro-40), and three (Fendrix group) 
participants.
Possible confounders of our primary outcome (smoking, age, baseline anti-HBs titre, 
diabetes, body-mass index, and sex) were similar between all study groups (table 
1). The intervals between vaccine doses and titre measurement after completion 
of the primary and revaccination series were similar in all study groups (appendix 
p 1). 16 (3%) of the 480 participants had a minimum 3 week interval between the 
first two doses of the primary series: six in the control group, four in the Twinrix 
group, two in the HBVaxPro-40 group, and four in the Fendrix group. 20 (4%) of 
the 468 participants who started the revaccination series had an interval during 
revaccinations between 3 weeks and less than 4 weeks. Of the participants with a 
revaccination interval of less than 4 weeks, five were in the control group, two in the 
Twinrix group, six in the HBVaxPro-40 group, and seven in the Fendrix group. Table 
2 shows the antibody response in the intention-to-treat analysis, 1 month after each 
revaccination (appendix p 3).
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For all study groups, the percentage of responders with an anti-HBs titre of 10 IU/L 
or more increased with each additional vaccine dose, as did geometric mean titres. 
After the third revaccination, an anti-HBs titre of 10 IU/L or more was observed in 
83 (67%) of 124 participants in the control group, in 94 (80%) of the 118 participants 
in the Twinrix group, in 95 (83%) of the 114 participants in the HBVaxPro-40 group, 
and in 108 (87%) of the 124 participants in the Fendrix group. The difference in the 
proportions of responders between the study groups and the control group after the 
revaccination series, adjusted for a centre-effect, ranged from 21·6% to 26·3%. The 
difference in proportions were significant for HBVaxPro-40 and Fendrix compared 
with the control group (table 3). The GMTs after revaccination were higher in all study 
groups compared with the control group, with a GMT ratio of 2·8 (95% CI 1·4–5·3) 
between Twinrix and the control group, 3·7 (2·1–6·7) between HBVaxPro-40 and the 
control group, and 5·4 (2·9–10·3) between Fendrix and the control group (table 3). 
Significantly higher GMT ratios were detected for the HBVaxPro-40 group and Fendrix 
group compared with the control group.
Table 3. Difference in anti-HBs antibody titres between study vaccines and control after completion of 


















 0·0204 26·3% 
(15·4-37·3)
 0·0006







Difference in serological response 4 weeks–3 months after third revaccination between vaccine groups 
adjusted for centre-effect regarding the proportion of responders with an anti-HBs titre ≥10 IU/L (%; 95% 
CI) and the corresponding GMT ratio (95% CI). Bonferroni corrected p values are shown (three times the p 
value).
As expected, there were slightly larger differences in proportions of responders 
between the control group and HBVaxPro-40 group or Fendrix group in the per-
protocol analysis (appendix p 1). The number of participants with an anti-HBs titre 
of 100 IU/L or more after three revaccinations was lowest in the control group; 47 
(38%) of 124, followed by 55 (47%) of 118 in the Twinrix group, 63 (55%) of 114 in 
the HBVaxPro-40 group, and 83 (67%) of 124 in the Fendrix group (figure 2A) The 
results presented after stratification by anti-HBs concentrations at baseline showed 
a protective immune response in 140 (64%) of the 219 participants with a baseline 
anti-HBs titre less than 1 IU/L. By contrast, the protective immune response was 
present in 208 (91%) of the 229 participants with baseline anti-HBs titres of 1–9·9 
IU/L (appendix p 2).
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Figure 2a,b. Reverse cumulative distribution curve at baseline and after revaccination. A) anti-HBs titres 
at baseline; B) anti-HBs titres after third revaccination
Myalgia was the most frequent systemic reaction and pain at the injection site the 
most frequently reported local reaction up to 7 days after revaccination (table 4). 
Differences in adverse events between vaccine groups were detected for myalgia and 
pain at the injection site after all doses, for oedema after dose 1 and 3, for erythema 
after dose 1, and for fever after dose 2 (table 4). Participants in the Fendrix group 
4
Chapter 4
reported more severe symptoms than did participants of the other vaccine groups. 
These symptoms were however transient and nearly all resolved spontaneously 
within 1 week. There was no increase in the number of adverse events observed after 
the administration of additional doses. One serious adverse event was reported in the 
Fendrix group: 4 days after the second revaccination, the participant was admitted to 
hospital and diagnosed with herpes zoster ophthalmicus. The researchers considered 
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Discussion
To our knowledge, this is the first randomised, controlled trial involving non-
responders after primary immunisation against hepatitis B that compares the 
immunogenicity of three different licensed vaccines with the standard revaccination 
schedule in the Netherlands. HBVaxPro-40 and Fendrix elicited higher proportions 
of responders as well as higher anti-HBs antibody titres after three revaccinations 
than the Engerix-B and HBVaxPro-10 control group. Administration of Twinrix did 
not result in a significantly higher proportion of responders or higher antibody titres 
after three revaccinations.
The superior immunogenicity of HBVaxPro-40 and Fendrix suggests that both 
a higher antigen dose in the hepatitis B vaccine and a more potent adjuvant are 
probably effective in increasing the antibody response against HBsAg. These results 
are only partly in line with David and colleagues’ systematic review comparing 
different options for vaccination management of healthy non-responders.17 Their 
analysis of pooled seroconversion rates compared, among others, additional 
intramuscular vaccinations with a HBsAg dose of 40 μg (IM-40) with intramuscular 
vaccinations with 20 μg (IM-20) of HBsAg. The IM-40 resulted in seroconversion 
rates that were similar to those of IM-20 after the first revaccination. However, 
seroconversion rates after the second and third revaccinations with IM-40 were even 
poorer than the IM-20 rates. A possible explanation for the better response of the 
IM-20 group could be that the results of different IM-20 vaccines (including AS04-
adjuvanted and alum-adjuvanted vaccines) were pooled together. In addition, the 
systematic review included studies with a different number of vaccinations before 
enrolment that might have hampered the comparability of these studies. Including 
participants with four vaccinations or more before revaccination could bias towards 
the selection of non-responders with virtually no antibodies against HBsAg, which 
could lead to poorer outcomes for anti-HBs seroconversion rates.
Our study did not show a significant difference in proportions of responders or 
difference in antibody titres, after revaccination with Twinrix compared with the 
control group results. In an earlier study, a double dose Twinrix showed a high anti-
HBs response rate of more than 90% in hepatitis A naive participants.14 This difference 
might be due to the inclusion of participants immune to hepatitis A and the use of a 
single dose of Twinrix in our study. Our results suggest that the downside of improved 
immunogenicity of Fendrix is that reactions at the injection site are more common 
than with the other vaccines, as seen in other studies.13,24 Our open-label design could 
have influenced the registration of solicited symptoms because the participants and 
local staff were aware of the specific vaccine received. Although severe local and 
general symptoms were more often reported in the Fendrix group, the vaccine was 
well tolerated as vaccination completion rates of the full revaccination series were 




Anti-HBs concentrations at baseline (zero responders vs 1–<10 IU/L [poor responders]) 
were equally distributed among the different types of vaccines used. However, 
baseline anti-HBs concentrations were the greatest response predictor in our 
regression model, as was also seen in previous studies.5,10 After stratification according 
to baseline anti-HBs concentrations, we found that the type of vaccine used in the 
revaccination series only affected the zero responder group. By contrast with the zero 
responder group, the group of poor responders had a high percentage of responders 
of approximately 90% in all study groups, regardless of the vaccine used. The primary 
titre height can be used in managing non-responders, albeit differences in assays 
used to assess anti-HBs antibody concentrations should be taken into account.
Novel adjuvanted vaccines such as HepB-CpG (Heplisav-B), a vaccine against 
hepatitis B with small synthetic immunostimulatory cytidine–phosphate–guanosine 
oligodeoxynucleotide (CpG-ODN) motifs (1018 adjuvant), have been developed. The 
1018 adjuvant binds to Toll-like receptor 9 to stimulate a directed immune response 
to HBsAg. Whether these immunostimulatory sequence adjuvanted vaccines will 
help to overcome non-response after hepatitis B vaccination is not yet clear.25 Larger 
studies are needed to identify the exact value of this novel registered vaccine and 
other experimental vaccines.26
We expect the internal validity of our trial to be good, with a low risk of bias on the 
basis of the following assessment items from the Cochrane bias assessment checklist. 
There is a low risk of selection bias in the random sequence generation, although the 
block size was small (four). Such a block size was regarded as potentially insufficient 
to completely conceal allocation sequence.27 However, a comparison of every first 
and fourth participant revealed no significant differences in baseline characteristics 
or in the percentage of responders at month 3. We believe a possible detection 
bias for the primary outcome is low because laboratory personnel and researchers 
of outcome assessment were masked. We believe that there was also little risk of 
attrition bias because of the high rate of vaccination completion in all study groups 
and missing outcomes are balanced across the intervention arms. We consider the risk 
of reporting bias low, because we reported on all outcome measures, both primary 
and secondary. Unlike the prespecified study protocol outcomes, we considered the 
anti-HBs titre height to be a secondary outcome. The height of the titre is relevant to 
better understand the immunogenicity of a vaccine against hepatitis B since higher 
antibody titres are correlated to a better long-term presence of vaccine-induced 
anti-HBs antibodies. However, the decision to use a specific vaccine is in our opinion 
primarily based on the proportion of responders, as this is correlated to protection 
against clinically relevant hepatitis B infections.
Our study has some limitations. First, few studies documented long-term 
protection after revaccination with a titre of 10 IU/L or more compared with the 
well-established evidence originating from long-term follow-up studies of primary 
vaccination series.3,10 Long-term protection after revaccination with a titre above the 
cutoff is, however, plausible. Immunocompetent individuals in this study received 
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a licensed primary vaccination schedule and three revaccinations that probably 
induced the important immunological memory for future exposure. Some countries 
define protective immunity after hepatitis B vaccination to be above an anti-HBs 
cutoff of 100 IU/L.28,29 The number of participants that had an anti-HBs titre of 100 
IU/L or more after three revaccinations in this trial was the lowest in the control 
group and the highest in the Fendrix group. Second, not all centres registered the 
number of candidates who were asked to participate in this study and the number 
who eventually declined. We based the participation rate on estimates at centres 
that did register the numbers and most candidates agreed to participate. This is not 
surprising: hepatitis B vaccination in adults in the Netherlands is indicated for high-
risk groups, which motivates those at risk to obtain seroprotection against hepatitis 
B. As we have no information about the candidates who declined to participate, we 
do not know whether this affected the external validity of our trial. However, our 
participants came from our target group, so we expect the external validity to be 
good with a low risk of generalisability bias. Third, the minimum interval between 
first and second doses of the primary vaccination series and the revaccination doses 
was set at 3 instead of 4 weeks, on the basis of Dutch travel health recommendations. 
In general, shortening of the vaccination interval results in lower antibody titres, 
and might overestimate the percentage of non-response to the primary vaccination 
schedule. Only 16 (3%) of the 480 participants of the primary series and 20 (4%) of 
the 468 participants who started the revaccination series had an interval between 
3 and 4 weeks. Owing to the limited number of participants with a minimum time 
interval between vaccinations of at least 3 weeks, we regard a possible effect of lower 
antibody titres of these participants to be negligible. As these participants are evenly 
distributed between control and intervention groups, this effect most probably did 
not affect our primary outcome results.
In conclusion, most non-responders after a primary vaccination series reached 
protective antibody concentrations against hepatitis B after three revaccinations. 
Revaccination with Fendrix or HBVaxPro-40 resulted in significantly higher 
antibody titres and proportions of responders than revaccination with Engerix-B 
or HBVaxPro-10 and therefore indication for these vaccines should be expanded to 
enable revaccination of non-responders.
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Data Sharing
For the RESPONS trial, at publication of related articles, data will be made available 
to the public. Owing to the privacy and intellectual property rights legislation, 
published data will in principle be anonymised/deidentified participant data, 
including the metadata and documentation necessary for the discovery and correct 
interpretation of the data. This contributes to the FAIRness of the project data. Data 
will be made available via Radboud University’s RIS interface to the public in the 
CoreTrustSeal certified DANS EASY archive. The DANS EASY archive is based on Dublin 
Core metadata and includes the assignment of a persistent identifier (DOI) to the 
data. Data will be available for the long term, at least for the required 10 years set 
by the Radboud University Research Data Management policy. Data will be made 
available via a Restricted Access licence (automated access on request via DANS EASY, 
by signing a data use agreement to guarantee the correct reuse of the data).
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Research in context
Evidence before this study
Non-protective immunity after a hepatitis B vaccination series occurs in 5–30% 
of healthy adults, depending on age, and it has major implications for individuals 
at high risk of hepatitis B. We searched PubMed using the following keywords in 
different combinations: “vaccination”, “vaccine”, “recombinant vaccine”, “hepatitis 
b virus”, “HBV”, “hepatitis B infection”, “nonresponders”, “non-responders” and “non 
responders” for clinical trials comparing immunogenicity for hepatitis B vaccines in 
healthy non-responding adults between Jan 1, 1986, and May 1, 2018. We updated the 
search between May 1, 2018, and Oct 1, 2019; we can confirm that with these search 
items no similar study has been published in the past year. Previous clinical trials 
compared different administration routes, vaccines with different antigen doses or 
additional adjuvants, and additional doses given to non-responders after hepatitis B 
vaccination. However, these studies show great diversity; they had design limitations, 
and in general they had a small sample sizes that limited the evidence-based rationale 
for recommendations in guidelines regarding healthy non-responders.
Added value of this study
To our knowledge this is the first randomised controlled trial that compares the 
immunogenicity of three registered hepatitis B vaccines. Revaccination with Fendrix 
or HBVaxPro-40 resulted in significantly higher antibody titres and proportion 
of responders after three vaccine doses than revaccination with Engerix-B or 
HBVaxPro-10 did.
Implication of all available evidence
Non-responding individuals after a primary series of hepatitis B vaccinations are at 
risk of contracting hepatitis B. The indication for a vaccine with a higher antigen dose 
or an monophosphoryl lipid A-adjuvanted vaccine should be expanded to enable 
revaccination of non-responders, especially in those with antibody titres of less than 
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table S1. Intervals between vaccine doses and titre measurement after completed primary and 
revaccination series in the intention-to-vaccinate analyses
 Control Twinrix HBVaxPro-40 Fendrix
Primary series,days
  Vaccination 1-2 32 (28-36) 34 (28-37) 33 (28-35) 33 (29-35)
  Vaccination 2-3 165(154-195) 161(154-175) 163 (154-185) 162 (154-183)
Titre measurement after primary 
series, days
40 (32-43) 42 (35-49) 42 (35-49) 42 (35-48)
Interval between titre measurement 
primary series and start 
revaccination, days
42 (28-80) 45 (28-73) 51 (27-95) 44 (30-73)
Revaccination series, days
  Vaccination 1-2 32 (28-35) 32 (28-35) 32 (28-35) 31 (28-35)
  Vaccination 2-3 33 (28-35) 34 (28-35) 32 (28-35) 31 (28-35)
Titre measurement after revaccination 
series, days
37(31-42) 38 (33-42) 39 (32-42) 35 (32-42)
Data are median (IQR)
table S2. Difference in anti-HBs antibody titres between study vaccines and control after completion 


















 0·0014* 32·9% 
(22·5-43·2)
<0·0001*
GMT ratio 2·5 (1·4-4·6) 0·1241 4·2 (2·3-7·6) <0·0001* 7·9 (4·3-14·3) <0·0001*
Difference in serological response four weeks to three months after third revaccination between vaccine 
groups adjusted for centre-effect regarding the proportion of responders with an anti-HBs titre ≥ 10 IU/l (%; 
95% CI) and the corresponding GMT ratio
* p<0·05 for Bonferroni corrected p-value (three times the p-value)
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table S3. Serological response at month 3 after stratification by primary titre height: anti-HBs < 1 IU/l 
vsanti-HBs 1 -9·9 IU/l
Baseline anti-HBs 
titre height [IU/l]


































Serological response four weeks to three months after third revaccination with the proportion of 
participants with an anti-HBs titre ≥ 10 IU/l expressed as n/N (%; 95% CI)









figure S2. Reverse cumulative distribution curve for revaccination titres at month 1 and 2. A) titre after 
first revaccination; B) titre after second revaccination
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Fluctuation of viremia in hepatitis B virus 
infected healthcare workers performing 
exposure prone procedures
Stijn F.H. Raven, Barry de Heus, Albert Wong, 
Hans L. Zaaijer, Jim E. van Steenbergen





To determine the longitudinal changes in viral load of hepatitis B virus (HBV)-infected 
healthcare workers (HCWs) and its consequences for exclusion of infected HCWs 
performing exposure-prone procedures (EPPs); for various HBV DNA safety thresholds 
and for the frequency of monitoring.
Design
Retrospective cohort study, June 1, 1996-January 31, 2013.
Participants: In The Netherlands, chronically HBV infected HCWs performing exposure-
prone procedures are notified to the Committee for Prevention of Iatrogenic Hepatitis 
B. Of the 126 notified HCWs, 45 had 2 or more HBV DNA levels determined without 
antiviral therapy.
Methods
A time-to-event analysis for HBV infected HCWs categorized in various viremia levels 
surpassing a HBV DNA threshold level of 1×105 copies/mL, above which exposure-
prone procedures are not allowed in the Netherlands.
Results 
Fluctuations of HBV DNA in follow-up samples ranged from -5.4 to +2.2 log10 copies/
mL. A high correlation was seen for each HBV DNA level with the 3 previous levels. 
In a time-to-event analysis, after 6 months 7.2%, 6.5%, and 14.3% of individuals had 
surpassed the threshold of 1×105 copies/mL respectively for viral load categories 
4.8×103 to 1.5×104, 1.5×104 to 4.0×104 and 4.0×104 to 1.0×105 respectively.
Conclusions
We propose standard retesting every 6 months, with more frequent retesting just 
below the high threshold value (1×105 copies/mL), and prolonging this standard 
interval to 1 year after 3 consecutive levels below the threshold in policies with lower 
safety thresholds (1×103 or 1×104 copies/mL).
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Introduction
Despite universal childhood vaccination in more than 180 countries,1 antenatal 
screening programs and vaccination programs directed at high-risk groups, hepatitis 
B remains a worldwide public health problem.2 Globally 240 million people are 
chronically infected with hepatitis B virus (HBV).3 Major HBV transmission modes are 
childbirth, blood-blood contact and unprotected sex.1 A mode of transmission that 
drew attention in the industrialized world over the past decades is the transmission 
of HBV from infected healthcare workers (HCWs) to patients, first described in 1970.4 
Since then, at least 52 HBV-infected HCWs have been implicated in the transmission 
of HBV to more than 500 patients in Europe and North America.5,6 Most of these 
cases are associated with exposure-prone procedures (EPPs), where there is an 
increased risk of the HCW experiencing a percutaneous injury, thus exposing the 
patient to the HCW’s blood.7 To reduce the risk of HBV transmission in the healthcare 
setting, occupational and hygienic guidelines have been developed on the basis of 
3 strategies: prevention of infection of HCWs, identification of infected HCWs, and 
restricting infectious HCWs from performing EPPs.6
In 2003 a European consensus group recommended that HBV infected HCWs 
should not perform EPPs if their HBV DNA level exceeds 1×104 copies/mL.6 Despite 
these recommendations guidelines with various HBV DNA cutoff levels have been 
established. Dutch guidelines ban HBV infected HCWs from performing EPPs if their 
HBV DNA level exceeds 1×105 copies/mL (i.e. 2×104 international units [IU]/mL).8 In the 
United Kingdom a cut-off level of 1×103 copies/mL is recommended.9 In the United 
States 2 guidelines coexist with the Centers for Disease Control and Prevention10 
and the Society for Healthcare Epidemiology of America11 advising safety HBV DNA 
thresholds of 5×103 genome equivalents/mL and 1×104 genome equivalents/mL 
respectively. A viral load expressed in copies/mL approximates to a load expressed 
in genome equivalents/mL. The choice for a certain threshold level results from a 
trade-off between the risk of transmission of HBV to patients and the loss of highly 
educated professionals.12 The Dutch rationale for the relatively high threshold of 1×105 
copies/mL is that only 1 report describes HBV transmission to a patient by an HCW 
with a viral load below 1×105 copies/mL, which in addition was measured several 
months after the actual transmission occurred.13,14 Realizing its distinct position, the 
Dutch Committee for Prevention of Iatrogenic Hepatitis B, (hereinafter referred to 
as the Committee) undertook to analyze HBV viral load dynamics of HBV in notified 
Dutch infected HCWs. It is important to understand fluctuations of HBV viral load 
in symptom free HCWs, because these fluctuations may jeopardize the safety of 
patients. Several studies report fluctuations in hepatitis B patients,15-17 however 
data from healthy HCWs are scarce.18 Uncertainty remains about the magnitude 
of viral load fluctuation in HBV infected medical personnel. Here we report on the 
dynamics of HBV viremia among notified HCWs with chronic hepatitis B infection 




various HBV DNA safety thresholds, above which an infected HCW is not allowed to 
perform EPPs.
Methods
In the Netherlands every HBV-infected HCW performing EPPs must be reported to the 
Committee for evaluation and advice. The establishment, aims and authority of the 
Committee have previously been described.19 From June 1, 1996 through January 31, 
2013, in total 126 HCWs were reported to the Committee. From its files the Committee 
extracted strictly anonymized data for this analysis, including gender, age, profession, 
EPP status, serial HBV DNA levels and antiviral treatment (if applicable). Missing data 
were obtained by contacting the attending physician and laboratory. According to 
Dutch legislation this study did not need an ethics approval. For 45 of the 126 notified 
HCWs with chronic hepatitis B infection 2 or more valid measurements of HBV DNA 
without interference of antiviral therapy were available for analysis of natural HBV 
load fluctuation.
The serial HBV DNA levels of the HCWs were determined in various laboratories 
using different assays, over 17 years. However, all participating laboratories are 
required to be officially certified for medical microbiology testing. All laboratories 
have to participate once yearly in a masked quality control program, showing good 
results for quantitation of HBV DNA.
The reported HBV DNA levels were expressed in copies/mL or in IU/mL. Viral loads 
expressed in IU/mL were converted to copies/mL assuming that 1IU equals 5 copies 
of HBV DNA.20,21
The lower limit of detection of the HBV DNA assays that were applied varied over 
time and per laboratory. To enable comparison of negative test results and positive 
test results below the lower limit of quantitation, standardization was performed 
as follows. Results being reported as “negative” were arbitrarily given a value of 10 
copies/mL. For test results below the lower limit of detection of an assay, a value 
was arbitrarily assigned to the rounded log10 value directly below the lower limit of 
detection (e.g: a test result of <300 copies/mL was converted to 100 copies/mL). HBV 
DNA levels above the upper limit of quantitation arbitrarily were assigned the value 
of the rounded log10 directly above that limit. The first available HBV DNA level for 
each HCW was chosen to be the baseline value of that person.
HBV DNA viral load fluctuations were analyzed, taking into consideration different 
threshold levels above which EPPs are prohibited. A time-to-event analysis was 
conducted to evaluate the time it took to surpass the Dutch cut-off level of 1×105 
copies/mL after the baseline viral load was established. We used a Cox proportional 
hazards model to describe the risk of an event at any given measurement time, 
given the covariates age, sex and viral load level. Persons with HBV levels below 
4,800 copies/mL never surpassed the Dutch threshold of 1×105 copies/mL at the next 
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measurement. These observations were excluded from the Cox proportional hazard 
model (as this requires at least some measurements to surpass the threshold value). 
The 100 remaining HBV DNA levels were categorized in 4 categories of roughly equal 
numbers (n≈25): 4.8 ×103 to 1.5 ×104; 1.5 ×104 to 4.0 ×104; 4.0 ×104 to 1.0 × 105; 1.0 ×105 
to 1.0 × 109 copies/mL.
Every measurement performed in an individual was defined as a new origin 
point in this analysis. Because this introduces clustering in the data, the analysis was 
performed using Survival (R foundation for Statistical Computing), which allows for 
adjustment of standard errors for clustering in observations.
Results
Considering the Dutch threshold level for performing EPPs of 1×105 copies/mL, 35 
of 45 HCWs had a baseline viral burden below this limit. During a mean follow-up 
of 5.2 years, 6 of 35 HCWs surpassed this level. Regarding the proposed European 
consensus level of 1×104 copies/mL, 27 HCWs with baseline levels below 1×104 copies/
mL at baseline were available for analysis; 11 of 27 HCWs surpassed the threshold of 
104copies/mL, of which 4 HCWs surpassed > 100,000 copies/mL in a mean follow-up 
of 5.3 years. In the United Kingdom the threshold above which staff is banned from 
EPPs is 1×103copies/mL. Nineteen HCWs showed baseline levels equal to or less than 
1×103 copies/mL and could be followed up: 14 of 19 HCWs surpassed the 1×103 copies/
mL limit in a mean follow up of 5.5 years . Six of these HCWs surpassed the threshold 
of 10,000 copies/ml and none exceeded the 100,000 copies/mL cut-off.
Demographic characteristics, follow up duration and HBV DNA levels are 
summarized in Table 1. The median (range) HBV viral load was 2.5 ×103 (10 to 5.0 ×108) 
copies/mL. A high correlation was seen for each HBV DNA level with the 3 previous 
loads, with correlation coefficients of 0.98, 0.97 and 0.96 respectively.
Regarding a threshold level of 1×105 copies/mL, 2 HCWs surpassed this upper limit 
after 3 previous DNA values below this level. Applying a threshold value of 1×104 and 
1×103 copies/mL, respectively 5 and 4 HCWs surpassed this threshold value after 3 
previous lower loads. However, none of these 9 HCWs surpassed an upper limit of 




table 1. Characteristics of 45 healthcare workers (HCWs) with Chronic Hepatitis B Virus (HBV) Infection
Variable Value
Age at baseline, y, mean (SD) 37.3 (12.0)
Sex, no. (%)*
  Male 26 (58)
  Female 18 (40)
Median duration of follow-up, y (range) 4.2 ( 21 d - 12 y)
No. of measurements
  Total 292
  Median (range) 4 ( 2 - 18)
Interval between measurements, median (range) 6.5 mo. (20 d - 6 y)
Baseline load (HBV DNA copies/mL) median (range) 5.0 × 103 (10 – 5.0 × 108)
Overall load (HBV DNA copies/mL) median (range) 2.5 × 103 (10 – 5.0 × 108)
*data were not available for 1 person.
table 2. Comparison of 45 healthcare workers (HCWs) infected with Hepatitis B Virus (HBV), categorized 
according to the maximum increase or decrease of their HBV DNA level, observed during total follow-up 




Observed during total follow-up 
compared to baseline
Observed over subsequent 
measurements









None 9 (20) 6 (13.3) 9 (20) 6 (13.3)
<1 11(24.4) 12 (26.7) 13 (29.9) 14 (31.1)
1−2 17(37.8) 16 (35.6) 21 (46.7) 19 (42.2)
2−3 5(11.1) 8 (17.8) 2 (4.4) 5 (11.1)
>3 3 (6.7) 3 (6.7)  …  1 (2.2)
Longitudinal Changes of Serum HBV DNA Levels
Maximum HBV DNA fluctuations during total follow-up compared with baseline load 
within individual HCWs were computed (Table 2). Three HCWs showed increases 
greater than 3 log10 copies/mL during total follow-up (e.g. 3.05, 3.18 and 3.4 log10 
copies/mL) compared with a baseline load over a period respectively of 10, 14 and 
21 months. Three HCWs showed a decrease of greater than 3 log10 copies/mL.
Maximum increase or decrease in a subsequent HBV DNA load measurement is 
shown in Table 2. The maximum increase in 2 subsequent measurements was 2.2 
log10 copies/mL, which occurred in 2 HCWs (4%). In one HCW this concerned a change 
from 7.1 × 103 to 1.2 × 106 copies/mL over a period of 16 months, and in the other this 
was a change from 1.0 × 102 to 1.7 × 104 copies/mL over a period of 5 months. The 
137
Fluctuation of hbv viremia in hcws
largest decline was a 5.4 log10 decrease in 2 subsequent samples with an interval of 
6 years and a conversion from hepatitis B e antigen positivity to anti-hepatitis B e 
antigen status.
Time Span to Surpassing the Threshold Value
The Cox proportional hazards model showed that, compared with the baseline 
category (4.8 ×103 -1.5 × 104), the higher the viral load category the higher the hazard 
rate change (i.e. an increased risk of exceeding the threshold value of 105 copies/mL at 
the next measurement). However, only in the highest category (1.0 × 105 - 1.0 × 109) is 
the hazard ratio significant. Also, in the Dutch policy this category is already banned 
from EPP from the start at baseline. Age and sex add little explanatory value in this 
analysis (Table 3). The survival curves per load category are plotted in Figure 1. To 
show their relationship with the current recommended frequency of measurements 
(each 6 months), the 6 month time span is depicted in the figure. The category 1.0 × 
105 to 1.0 × 109) has the lowest survival rate, because these baseline loads already start 
above the cut-off of 1 ×105 copies/mL. After 6 months the percentages of individuals 
that exceeded the cut-off were 7.2%, 6.5%, 14.3% and 31.4% respectively for category 
4.8 ×103 to1.5 ×104, 1.5 ×104 to 4.0 ×104, 4.0 × 104 to 1.0 ×105 and 1.0 ×105 to 1.0 ×109.
Table 3. Results of Cox proportional hazards model with hazard ratios (HRs) for different viral load 
categories, age and sex
Variable Estimated HR* (CI 95%) P value
Load category (4.8 x 103 to 1.5 x 104) 1.00 (Reference)
Load category (1.5 x 104 to 4.0 x 104) 1.36 (0.22-8.27)  .76
Load category (4.0 x 104 to 1.0 x 105) 2.50 (0.37-16.83)  .40
Load category (1.0 x 105 to 1.0 x 109) 6.66 (1.33-33.49)  .04
Age 1.00 (1.00-1.00)  .93
Male sex 0.76 (0.29-1.99)  .65
HRs are relative to baseline category (4.8 x 103 to 1.5 x 104), where HR = 1 indicates no effect. HR> 1 suggests 
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figure 1. Proportions of 45 hepatitis B virus-positive (HBV+) healthcare workers (HCWs), subdivided into 
4 groups based on their HBV DNA levels, not surpassing a safety level of 1 ×105 copies/mL HBV DNA, 
above which exposure-prone procedures are not allowed. Survival curves were constructed from a Cox 
proportional hazards model. The solid black lines represent the survival curves. The dotted black lines 
are the 95% confidence intervals. The vertical red line represents the current measurement frequency 
of 6 months.
Discussion
To shed light on the natural fluctuation of HBV DNA levels in HCWs, we analyzed a 
large group of HBV-infected HCWs. We observed HBV DNA fluctuations in follow-
up samples ranging from -5.4 to +2.2 log10 copies/mL. However, focusing on rises 
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during total follow up, most (37 [82.2%]) did not show rises greater than 2 log10. 
This is consistent with other studies that also showed continuous fluctuations in 
symptomless HBV carriers within limited ranges.18,22 Cacciola et al18 evaluated a small 
cohort of 13 inactive HBV carriers for 12 months with HBV DNA fluctuations between 
1 and 2 log10 changes, with all levels below an upper value of 2 ×10
4 copies/mL. 
Croagh et al22 concluded that minor fluctuations in HBV DNA up to 2 ×104 IU/mL 
(ie. 1 ×105 copies/mL), accompanied by persistently normal alanine transaminase 
level, occurred frequently in hepatitis B e antigen-negative chronic hepatitis B, with 
a median follow-up of 2 years.
To compensate for natural fluctuations of HBV viremia, implementing a lower 
threshold above which EPPs are forbidden reduces the transmission risk by definition. 
Unfortunately, data are scarce on the risk of provider to patient-transmission related 
to the exact level of HBV viremia at time of the transmission incident.6,10,23 Among our 
personnel it was observed that indeed none of the HCWs with baseline HBV loads less 
than 1 ×103 copies/mL surpassed 1 ×105 copies/mL at any subsequent measurement, 
against 4 (15%) of 27 HCWs with baseline loads less than 1 ×104 copies/mL and 6 out 
of 35 (17%) HCWs with baseline loads less than1 ×105 copies/mL.
The Dutch policy for HBV-infected healthcare providers allows the highest 
threshold value to conduct EPPs compared with other countries and consequently 
has the smallest safety margin to compensate for natural fluctuation of HBV DNA 
levels. The Cox proportional hazards model shows that the higher the initial HBV 
load, the greater the hazard ratio. In other words the higher the previous HBV load 
the greater the risk of surpassing the threshold value at the next measurement. This 
raises the question of what interval between control measurements is sufficient 
to minimize EPPs with DNA levels above the threshold. Our data suggest a strict 
follow-up of personnel with HBV DNA above 4.8x103 copies/mL, because in this group 
approximately 7% will exceed the threshold of 105 copies/mL after 6 months. In HBV 
DNA levels just below the threshold (ie. 4.0 ×104 to 1.0 ×105) we consider a shorter 
retest policy -for example after 3 months- preferable because of the small Dutch 
safety margin and increased risk of exceeding the threshold. However, because the 
confidence intervals of the survival plots in our analysis are wide, one can argue 
whether this shorter retest policy is justified.
A high correlation was observed for each HBV DNA level with the 3 previous loads. 
In our opinion, for guidelines that recommend lower safety threshold levels of 1 ×104 
and 1 ×103 copies/mL for HBV infected personnel, a less frequent monitoring interval 
is acceptable, if 3 consecutive HBV DNA measurements were all below the threshold. 
Although 9 HCWs did surpass the lower threshold levels during follow-up, none of 
them surpassed a threshold of 1 ×105 copies/mL during total mean follow-up of more 
than 5 years. In this situation we consider a lengthening of the monitoring interval 
to 1 year acceptable.
Strict follow-up of personnel with higher HBV loads serves also an individual 




predictor of hepatocellular carcinoma.24,25 Therapeutic efficacy of antiviral agents 
has improved in reducing HBV DNA levels significantly in recent years. Several 
guidelines recommend referral of highly viremic HCWs for antiviral treatment and 
close monitoring of HBV DNA levels.26-28 Subsequently, successful antiviral treatment 
of HBV-infected HCWs has resulted in lifting a ban on performing EPP.19
A limitation of this study is the assumption that HBV DNA measurements were 
random. This may not be the case because HCWs who are considered to pose a higher 
risk might be screened more often. However, our results did not confirm this difference 
in screening procedures because the mean interval between measurements of the 
lowest and highest baseline levels below the threshold of 1 ×105 copies/mL did not 
differ significantly (results not shown). Another limitation is the assumption that in our 
Cox proportional hazards model the observed event (ie. surpassing 1 ×105 copies/mL) 
occurred at the time of measurement, while in fact an event may have occurred earlier 
and was not witnessed, because at that time a measurement was not performed. In 
this respect our survival curves may reflect an optimistic view. During the natural 
history of HBV infection, HBV DNA levels differ according to one’s phase of disease 
(immune tolerant, immune clearance, non-replicative and the reactivation phase).29 
We lacked information on the length of the period following the diagnosis related 
to the HBV DNA measurements, and therefore we could not adjust for differences in 
time following diagnosis between individuals in our model. Another limitation is that 
the model is based on 4 groups of equal size instead of on clinically relevant groups 
based on cut-off values. This could have influenced our results. A larger data set can 
overcome this limitation in future research on this topic.
A final point that needs consideration is that different laboratories determined the 
HBV DNA levels using various assays. Studies have shown intra-assay and interassay 
variability for real time polymerase chain reaction and signal amplification techniques, 
with an estimated assay variation margin of 1 log10.
16,30-32 In the Committees’ guideline 
no uniform “testing practice” is prescribed, apart from the quality control standards 
that the Committee demands. The possible confounding by disturbance from testing 
variability in our study remains unclear.
Because of the viral load fluctuations in HBV-infected healthcare workers who 
perform exposure prone procedures, the ongoing monitoring of viral burden is 
essential for maintaining patient safety. HBV viremia fluctuations, combined with 
the monitoring interval, a limited precision of HBV quantification, and the scarcity 
of data on the link between HBV DNA levels and HBV transmission, demand a safety 
margin. We suggest a more tailored retest policy with standard retesting every 6 
months, with more frequent retesting just below the high threshold value (1 ×105 
copies/mL) and prolonging this interval to 1 year after 3 consecutive levels below the 
threshold in policies with lower safety values (1 ×103, or 1 ×104 copies/mL).
141
Fluctuation of hbv viremia in hcws
Acknowledgements
We thank Thea Daha for the collection and meticulous registration of the data and 
the laboratories for their cooperation with the Dutch Committee for Prevention of 
Iatrogenic Hepatitis B.
Financial support: Non reported






1. World Health Organization. Hepatitis B 
factsheet 204., 2012. (Accessed December, 9 
2014, at http://www.who.int/mediacentre/
factsheets/fs204/en/index.html.)
2. Gerlich WH. Prophylactic vaccination against 
hepatitis B: achievements, challenges 
and perspectives. Med Microbiol Immunol 
2015;204:39-55.
3. Ott JJ, Stevens GA, Groeger J, Wiersma ST. 
Global epidemiology of hepatitis B virus 
infection: new estimates of age-specific 
HBsAg seroprevalence and endemicity. 
Vaccine 2012;30:2212-2219.
4. Garibaldi RA, Rasmussen CM, Holmes AW, 
Gregg MB. Hospital-acquired serum hepatitis. 
Report of an outbreak. JAMA 1972;219:1577-
1580.
5. Carlson AL, Perl TM. Health care workers as 
source of hepatitis B and C virus transmission. 
Clin Liver Dis 2010;14:153-168; x.
6. Gunson RN, Shouval D, Roggendorf M, et 
al. Hepatitis B virus (HBV) and hepatitis 
C virus (HCV) infections in health care 
workers (HCWs): guidelines for prevention of 
transmission of HBV and HCV from HCW to 
patients. J Clin Virol 2003;27:213-230.
7. Deuffic-Burban S, Delarocque-Astagneau 
E, Abiteboul D, Bouvet E, Yazdanpanah Y. 
Blood-borne viruses in health care workers: 
prevention and management. J Clin Virol 
2011;52:4-10.
8. Ballemans C, Daha T, Frijstein G, et al. 
Landelijke richtlijn preventie transmissie 
van hepatitis B van medisch personeel naar 
patiënten. In: RIVM, ed. Bilthoven; 2012.
9. UK Department of Health. Hepatitis B 
infected healthcare workers and antiviral 





10. Centers for Disease C, Prevention. Updated 
CDC recommendations for the management 
of hepatitis B virus-infected health-care 
providers and students. MMWR Recomm Rep 
2012;61:1-12.
11. Henderson DK, Dembry L, Fishman NO, et al. 
SHEA guideline for management of healthcare 
workers who are infected with hepatitis 
B virus, hepatitis C virus, and/or human 
immunodeficiency virus. Infect Control Hosp 
Epidemiol 2010;31:203-232.
12. Buster EH, van der Eijk AA, Schalm SW. Doctor 
to patient transmission of hepatitis B virus: 
implications of HBV DNA levels and potential 
new solutions. Antiviral Res 2003;60:79-85.
13. Corden S, Ballard AL, Ijaz S, et al. HBV DNA 
levels and transmission of hepatitis B by 
health care workers. J Clin Virol 2003;27:52-58.
14. Updated CDC recommendations for the 
management of hepatitis B virus-infected 
health-care providers and students. MMWR 
Recomm Rep 2012;61:1-12.
15. Tedder RS, Ijaz S, Gilbert N, et al. Evidence 
for a dynamic host-parasite relationship in 
e-negative hepatitis B carriers. J Med Virol 
2002;68:505-512.
16. Plentz A, Koller G, Weinberger KM, Jilg W. 
Precision and stability of hepatitis B virus DNA 
levels in chronic surface antigen carriers. J Med 
Virol 2004;73:522-528.
17. Martinot-Peignoux M, Boyer N, Colombat M, et 
al. Serum hepatitis B virus DNA levels and liver 
histology in inactive HBsAg carriers. J Hepatol 
2002;36:543-546.
18. Cacciola I, Spatari G, Pollicino T, et al. 
Virological profiles in hepatitis B virus inactive 
carriers: monthly evaluation in 1-year follow-
up study. Liver Int 2005;25:555-563.
19. Daha TJ, Bilkert-Mooiman MA, Ballemans C, 
et al. Hepatitis B virus infected health care 
workers in The Netherlands, 2000-2008. Eur 
J Clin Microbiol Infect Dis 2009;28:1041-1044.
143
Fluctuation of hbv viremia in hcws
20. Nardone A, Anastassopoulou CG, Theeten 
H, et al. A comparison of hepatitis B 
seroepidemiology in ten European countries. 
Epidemiol Infect 2009;137:961-969.
21. Anna S.F. Lok BJM. AASLD Practice Guidelines: 
Chronic hepatitis B: Update 2009. Hepatology 
2009;50.
22. Croagh CM, Bell SJ, Chen RY, Locarnini S, 
Desmond PV. Longitudinal observation of viral 
load changes in untreated HBeAg negative 
chronic hepatitis B. Acta Gastroenterol Belg 
2013;76:275-281.
23. FitzSimons D, Francois G, De Carli G, et al. 
Hepatitis B virus, hepatitis C virus and other 
blood-borne infections in healthcare workers: 
guidelines for prevention and management 
in industrialised countries. Occup Environ Med 
2008;65:446-451.
24. Papatheodoridis GV, Chrysanthos N, 
Hadziyannis E, Cholongitas E, Manesis EK. 
Longitudinal changes in serum HBV DNA 
levels and predictors of progression during 
the natural course of HBeAg-negative chronic 
hepatitis B virus infection. J Viral Hepat 
2008;15:434-441.
25. Chen CJ, Yang HI, Su J, et al. Risk of 
hepatocellular carcinoma across a biological 
gradient of serum hepatitis B virus DNA level. 
JAMA 2006;295:65-73.
26. European Association For The Study Of The L. 
EASL clinical practice guidelines: Management 
of chronic hepatitis B virus infection. J Hepatol 
2012;57:167-185.
27. Bhat M, Ghali P, Deschenes M, Wong P. 
Hepatitis B and the infected health care 
worker: public safety at what cost? Can J 
Gastroenterol 2012;26:257-260.
28. van der Eijk AA, de Man RA, Niesters HG, 
Schalm SW, Zaaijer HL. Hepatitis B virus (HBV) 
DNA levels and the management of HBV-
infected health care workers. J Viral Hepat 
2006;13:2-4.
29. Alexopoulou A, Karayiannis P. HBeAg negative 
variants and their role in the natural history 
of chronic hepatitis B virus infection. World J 
Gastroenterol 2014;20:7644-7652.
30. Caliendo AM, Valsamakis A, Bremer JW, et al. 
Multilaboratory evaluation of real-time PCR 
tests for hepatitis B virus DNA quantification. 
J Clin Microbiol 2011;49:2854-2858.
31. Yang JF, Lin YY, Huang JF, et al. Comparison of 
clinical application of the Abbott HBV PCR kit 
and the VERSANT HBV DNA 3.0 test to measure 
serum hepatitis B virus DNA in Taiwanese 
patients. Kaohsiung J Med Sci 2009;25:413-422.
32. Schalm SW, Buster EH. Management of 
hepatitis B virus infected health care 








The overall aim of this thesis was to provide insights to the knowledge gaps existing 
in prevention of hepatitis B through vaccination and through case finding by means 
of active HBV testing in the Netherlands. In this chapter I will discuss the main findings 
of the previous chapters, provide recommendations and future policy directions 
for prevention strategies on hepatitis B, and put these in the perspective of recent 
literature and future research.
1 Prevention of hepatitis B: vaccination and the 
revaccination of non-responders
The current starting point for prevention of hepatitis B through vaccination is 
influenced by the previous vaccination policy in The Netherlands. The Netherlands 
opted initially for a vaccination policy targeted against several high-risk groups for 
HBV mainly because of the low prevalence of hepatitis B combined with hepatitis B 
transmission predominantly among high-risk groups. Compared to other countries 
the Netherlands started universal hepatitis B vaccination relatively late including 
hepatitis B vaccination in 2011 in the National Immunisation Programme. As a result, 
extensive targeted high-risk vaccination programs are in place for an adult population 
and these vaccination efforts need continuation until HBV transmission declines 
substantially in the targeted risk-group or the immunological effects of the childhood 
HBV vaccination reach an adult population.1-3 For example, a well-documented 
decline in HBV transmission was observed in people who use drugs (PWUD) in the 
Netherlands. Although this was mainly driven by the decline in injecting drug use and 
to a lesser extent driven by the effects of vaccination against HBV.4-6 Consequently, 
in 2012, the targeted high-risk vaccination program no longer regarded PWUD, 
including PWID, as a risk group to be tackled in a national vaccination campaign 
against hepatitis B.7 Most healthy adults develop a protective antibody response, 
defined as an antibody titre (anti-HBs) of 10 IU/L or more against hepatitis B surface 
antigen (HBsAg), measured 1 to 3 months after the last vaccination.8 However, 5–30% 
of healthy vaccine recipients (depending on age and sex) develop anti-HBs serum 
concentrations of less than 10 IU/L and are defined as non-responders. 9,10 11-13 General 
consensus on the optimal vaccination policy for non-responders was absent and is 
one of the knowledge gaps in vaccination against hepatitis B.
1.1 Revaccination of non-responders
Previous clinical trials that included non-responders after hepatitis B vaccination 
compared different administration routes, vaccines with different antigen doses or 
additional adjuvants, and additional doses given. However, these studies showed 
great diversity; they had design limitations, and in general they had a small sample 
sizes that limited the evidence-based rationale for recommendations in guidelines 
regarding healthy non-responders. Knowledge gaps existed in the performance of 
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currently used and commercially available anti-HBs diagnostic assays (addressed in 
chapter 3), which vaccine (chapter 4) and the optimal number of revaccinations 
(chapter 5) are most effective in inducing protective immunity in non-responders.
The results from chapter 3 showed that the use of different anti-HBs assays around 
clinically relevant cutoff values could hamper a reliable measurement of an anti-
HBs titre. Therefore, we used one assay measuring the anti-HBs titre, which was the 
primary outcome of the multicentre study of chapter 4. Compared to other anti-HBs 
assays the Architect assay has a tendency to give slightly lower and sometimes false-
negative anti-HBs results. In 2018, the re-standardized Architect assay with the 2nd 
WHO anti-HBs standard revealed an upward shift in the anti-HBs results, which might 
reduce the problem of false negative results for this assay.14 The prospective study 
described in chapter 4 was designed to overcome limitations stated in the previous 
paragraph. The randomized controlled study demonstrated that HBVaxPro-40 and 
Fendrix elicited higher proportions of responders as well as higher anti-HBs titres 
after three revaccinations than the Engerix-B and HBVaxPro-10 control group. After 
stratification by anti-HBs concentrations at baseline, the results showed a protective 
immune response in 140 (64%) of the 219 participants with a baseline anti-HBs titre 
below the limit of detection (less than 1 IU/L) regardless the vaccine used. In contrast, 
a protective immune response was present in 208 (91%) of the 229 participants with 
baseline anti-HBs titres of 1–9.9 IU/L, also regardless the vaccine used. The superior 
immunogenicity of HBVaxPro-40 and Fendrix suggests that both a higher antigen 
dose in the hepatitis B vaccine and a more potent adjuvant are probably effective in 
increasing the antibody response against HBsAg. These results shed light on the type 
of vaccines that can be used in the revaccination schedule of a healthy non-responder. 
The optimal number of revaccinations was further explored in chapter 5 based on the 
observation of the large difference in proportion of responders between participants 
with a baseline anti-HBs titre above or below the limit of detection. Baseline anti-HBs 
titres of non-responders were categorised between poor-responders, defined as 
non-responders with detectable but non-protective antibodies and zero-responders, 
defined as non-responders without detectable antibodies. We assessed in different 
assays whether the classification of non-responders based on the anti-HBs titre was 
reproducible, and if there was a difference in proportion of responders between 
zero- and poor-responders. We concluded from the results of four anti-HBs assays 
that the inter-assay agreement between the classification of zero-responders and 
poor-responders was fair with an k ≥ 0.65 except for the Advia (k ≤ 0.41). However, 
all assays demonstrated a comparable large difference in proportion of responders, 
with a significantly higher proportion of responders for the poor-responder groups 
compared to the zero-responder groups after one revaccination. Following these 
results we applied a titre-based revaccination strategy with a different number of 
revaccinations between poor- and zero-responders. The titre-based strategy resulted 
in a substantial mean reduction of 17% in vaccination consultations, at the expense of 




revaccination strategy. The reduction in the number of vaccinations by the titre based 
revaccination scheme brings a financial benefit. A recent cost-effectiveness study 
among non-responders comparing a standard revaccination scheme with a two-dose 
Heplisav-B revaccination scheme reported no cost-effectiveness for the use of this 
novel adjuvanted vaccine.15 A reduction in the number of revaccinations might alter 
a cost-effectiveness analysis in a titre based revaccination scheme despite an added 
cost-per dose in novel adjuvanted vaccines.
Improving the revaccination policy for non-responders after hepatitis B 
vaccination will have an impact on the individual level of the non-responder. The 
suggested revaccination schedules in this thesis will likely result in better serological 
protection against hepatitis B, which solves a practice-based problem frequently 
encountered in vaccination practice. However the existence of non-responders after 
hepatitis B vaccination will probably neither threaten an eradication of hepatitis B 
in the future, nor have a major impact on public health.16 The limited impact on the 
burden of disease of hepatitis B vaccine non-responders can be explained by the 
age-related risk of non-response after vaccination, the additional protection after 
revaccination, and the variable risk of infection as a non-responder.11,15 As most non-
responders are of an adult age, the risk of becoming chronically infected after a 
hepatitis B infection is small and consequentially the contribution to the burden of 
disease will be limited.17
1.2 (Re)vaccination completion
 In addition to the previous paragraph, a reduction in the number of revaccinations 
will probably improve patient compliance, as multidose hepatitis vaccine adherence 
and completion in adults has been demonstrated to be suboptimal.18-20 The results 
from chapter 2 showed that ‘organisational’ factors (e.g. the organisation that 
administered the vaccine and flexibility in vaccination location) were associated 
with improved vaccination completion of a primary hepatitis B vaccination schedule 
in PWUD. However other factors such as financial incentives and an accelerated 
vaccination schedule had also proved helpful in prior studies to improve vaccination 
completion rates in an unstable drug-using population.21-27 The study population of 
interest in most previous studies on vaccination completion were high-risk groups 
for hepatitis B and the generalisation of those results to the general public should 
be made with caution. However, it is plausible that a reduction in the number of (re)
vaccinations which reduces the time-span of the vaccination schedule would improve 
(re)vaccination completion in a general as well as a high-risk population. In that light, 
the approval by the Food and Drug Administration and more recently the European 
Medicines Agency of a novel adjuvanted hepatitis B vaccine is interesting.28,29 The 
vaccine HepB-CpG (Heplisav-B), is a vaccine against hepatitis B with small synthetic 
immunostimulatory cytidine–phosphate-guanosine oligodeoxynucleotide (CpG-
ODN) motifs (1018 adjuvant). The vaccine is administered in a primary schedule as 
two doses, 1 month apart. The number of vaccines and time interval is reduced, 
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which could improve vaccination completion, without a loss of immunogenicity if 
this schedule is applied.18,29,30
1.3  Other revaccination regimens for non-responders.
Other revaccination schemes have been suggested to overcome non-response after 
hepatitis B vaccination, such as alternate routes of administration of the vaccine, 
the use of vaccines with more immunogenic antigens (third generation vaccines) 
or adjuvants, or the co-administration of immunomodulatory medications, such 
as granulocyte macrophage colony-stimulating factor, levamisole, or praziquantel, 
with vaccination.31,32 A thorough studied route of administration is the intradermal 
application of the hepatitis B vaccine which might offer an immunological advantage 
over the intramuscular route of administration.33 Although seroconversion rates 
up to 90% have been documented in previous non-responders, the intradermal 
administration of vaccines requires expertise which is not easily available.32 Additional 
practical issues arise for the other management options as third generation vaccines 
are not registered in Europe and immunomodulatory medication is not readily 
available at general vaccination practices.1
1.4 Recommendations for practice and further research
To contribute to the HBV prevention through vaccination, improvement of the 
management of non-responders after hepatitis B vaccination can reduce the number 
of susceptible persons for a hepatitis B infection. Several recommendations to 
improve vaccination practice for non-responders can be made based on the findings 
of this thesis. First, the vaccines of choice are a vaccine with a higher antigen dose or 
a monophosphoryl lipid A-adjuvanted vaccine. These vaccines are not yet registered 
for this indication and this omission should be resolved. Second, the differentiated 
baseline anti-HBs titre should be used to determine the number of revaccinations 
followed by an anti-HBs titre control measurement. To enable this policy, a third 
recommendation is that laboratories should routinely complete the serology result 
of a non-responder with information whether the anti-HBs titre is above or below 
the assay’s limit of detection.
Improvement of vaccination series completion can further optimise the 
HBV prevention through vaccination. Convenience is key to improve hepatitis B 
vaccination programs in countries with ongoing HBV transmission among people 
who use drugs. Therefore, flexibility of vaccination location and administration of 
vaccines by healthcare workers with sustainable contact with PWUD is important and 
could improve vaccination programs for this risk group. As the number of vaccines 
and time interval is reduced in the novel registered HepB-CpG (Heplisav-B) this could 
improve vaccination completion as well. The vaccine HepB-CpG should be further 
explored in target groups for hepatitis B as the vaccine has been registered in the 




Further research on non-response after hepatitis B vaccination should focus on 
better vaccines that could overcome the immunological non-response. Whether 
novel vaccines, such as HepB-CpG, with their adjuvant based on immunostimulatory 
sequences will help to overcome nonresponse after hepatitis B vaccination is not 
yet clear.34 Larger studies are needed to identify the exact value of this novel 
registered vaccine and other experimental vaccines.35 Another possibility to 
overcome non-response could be the co-administration of an immunomodulatory 
vaccine. Evidence is accumulating on the additional heterologous effects (i.e. non 
disease specific effects) of Bacillus Calmette-Guérin (BCG) vaccination on other than 
mycobacterial pathogens. One of these effects might result from an enhancement 
of the immunological response to other vaccines with concomitant BCG vaccination 
or injection of BCG derived adjuvants.36,37 Recent studies suggest epigenetic 
reprogramming of innate immune cells, also called ‘trained immunity’ and cross-
protection induced by heterologous T-cell memory responses (heterologous 
immunity) as possible immunological mechanisms.38,39 These findings suggest BCG 
vaccination prior to HBV revaccination also as an interesting way to train innate 
immunity and consequently facilitate initiation of adaptive immunity. Up till now, 
very little is known on BCG adjuvanted HBV vaccination with one study conducted 
in mice and conflicting results of three studies conducted in children.37,40,41 Studies in 
adult non-responders have not yet been conducted to test the hypotheses whether 
prior BCG vaccination is of benefit to overcome non-response in this age-group. As a 
first randomized trial where BCG vaccination was given prior to a trivalent influenza 
vaccination significantly enhanced the antibody response against A(H1N1)pdm09 
in adults, the principle of vaccine induced immunomodulation is worth further 
exploring.42
Another hypothesis worth exploring to overcome nonresponse after hepatitis B 
vaccination is the influence of previous immunity of hepatitis A on the serological 
response of non-responders to hepatitis B vaccination. In a combined vaccine against 
hepatitis A and B (e.g. Twinrix) the hepatitis A antigen might act as an adjuvant for 
the serological response against the hepatitis B surface antigen.43
Few studies documented long-term protection after revaccination with a titre 
of 10 IU/L or more in previous non-responders compared with the well-established 
evidence originating from long-term follow up studies of primary vaccination 
series.8,10,44,45 Long-term protection after revaccination with a titre above the 
cutoff is, however, plausible. In our trial described in chapter 4 immunocompetent 
individuals received a licensed primary vaccination schedule and three revaccinations 
that probably induced the important immunological memory for future exposure. 
In addition, fortunately clinically important breakthrough HBV infections after 
vaccination are rare and mainly described in case reports and point to primary vaccine 
failure (anti-HBs below 10 IU/l), escape-mutant HBV strains and waning immunity as 
explanations of infection.46-48 As hepatitis B is a notifiable disease in many countries, 
including the Netherlands surveillance of the acute hepatitis B infections is in place 
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and could detect a possible breakthrough infection in a previous non-responder. 
In our proposed titre-based revaccination strategy the number of revaccinations 
to reach an anti-HBs titre greater than 10 IU/l can be reduced to one revaccination.
Ideally, a follow up study is conducted, for several years of seroconverted non-
responders in a high-risk setting to observe the long-term protection in previous 
non-responders. The number of revaccinations should also be documented to 
elucidate whether protection against hepatitis B infection is affected by the number 
of revaccinations. Alternatively, additional immunological correlates of protection 
against hepatitis B could be explored to better understand the immunological 
mechanisms of a non-response after hepatitis B vaccination.
2 Case finding of chronic hepatitis B patients in the 
Netherlands
To a large extent liver-related morbidity and mortality caused by a hepatitis B 
infection is preventable with the availability of long-term antiviral therapy.49 The 
morbidity did not decline over the years, despite access to improved treatment 
options for hepatitis B.50,51 52 As most CHB infections are asymptomatic and CHB 
contributes most to the burden of disease of hepatitis B17, improving the active case 
finding of CHB patients and referral to treatment if indicated is of utmost importance 
in the Netherlands. As current treatment suppresses viral replication, consequently 
HBV DNA levels are suppressed as well. The treatment’s reduction of HBV DNA 
levels can be used in specific situations, such as HBV–infected healthcare workers or 
highly viremic pregnant women, as a measure to prevent further transmission (i.e. 
treatment-as-prevention).53-56
Case finding of chronic hepatitis B (CHB) patients occurs in several screening and 
public health programs in addition to specific high risk situations in patient care 
(e.g. screening for HBV before the start of certain biologicals) in the Netherlands.57-59 
The contribution of sexual health centres on the number of detected CHB patients 
is still unknown. In addition to current screening programs to detect CHB patients, 
the Health Council of the Netherlands advised case finding by general practitioners 
(GP) for people in risk groups, case finding by institutions that are responsible 
for delivering care to people in risk groups (mainly related to previous or current 
injecting drug use) and finally local and regional screening programmes in cities 
and regions with relatively large groups of first-generation migrants.60 Prior to the 
Health Council advise, various independent small screening projects for CHB took 
place in the Netherlands among different migrant groups originating from middle- 
and high-endemic countries for hepatitis B.61-63 Despite these past efforts and 
currently implemented programs, annually approximately 500 patients die due to 
the complications of a viral hepatitis infection of which an estimated 200 patients 




2.1 Case finding and implications for HCWs
Not all CHB patients have an indication for therapy for hepatitis B virus, which 
depends on clinical parameters of HBV-related disease activity and progression. 
This enabled us to explore in chapter 7 the natural course of longitudinal changes 
in HBV viremia of HBV–infected healthcare workers (HCWs) and its consequences 
for exclusion of infected HCWs performing exposure-prone procedures. Current 
therapies for HBV inhibit viral replication and consequently suppress HBV DNA.51 
Above a safety threshold value of viremia, HBV antiviral therapy is required to allow 
the HCW to conduct further exposure prone procedures.65,66 We concluded from our 
results that a more tailored retest policy is possible. Unlike the standard practice, 
patient safety determines the indication for therapy, instead of disease progression 
of the CHB patient. This is an example of treatment-as-prevention, a concept that 
is also applied in the prevention of mother-to-child-transmission for hepatitis B. In 
mothers with high viremia, above a threshold of the viral load of 200.000 IU/ml, the 
risk of MTCT is increased despite infant immunoprophylaxis and peripartum antiviral 
therapy is advised.53
2.2 Case finding of chronic hepatitis B patients at sexual health centres
The Health Council acknowledged that MSM and CSW are a risk group for chronic 
hepatitis B and screening for HBV is already part of the national vaccination 
program in behavioural risk-groups for hepatitis B. Screening for HBV at the start of 
a vaccination series in these risk-groups is performed by sexual health centres. The 
report of the Health Council did not mention in their recommendations sexual health 
centres as a location for case finding for chronic hepatitis B patients although several 
risk groups stated in the report (CSW, MSM and to a lesser extend first generation 
migrants) frequently attend these clinics. In chapter 6 we estimated that sexual 
health centres in the Netherlands contributed approximately for 1 out of every 10 
notified CHB patients and that number remained stable over the years. With an 
ongoing HBV vaccination program for MSM and CSW and a documented decline of 
acute HBV infections among MSM, the case finding of CHB patients among sexual 
health centres may decline.67 However, the largest number of CHB patients was found 
among first generation immigrants originating from high endemic countries for STI. 
This is in line with literature on the prevalence of CHB in the Netherlands among 
FGM. Compared to other European countries the relative contribution of migrants 
to the overall CHB burden in the Netherlands is particularly high and comparable 
to some other Western and Northern European countries.68-70 If the number of 
chronic cases among first generation migrants will decline in the next decade(s) is 
dependent on the vaccination policy and additional interventions to successfully 
block the mother-to-child transmission (MTCT) in the country of origin. As the effects 
of these prevention programs will take several decades to protect an adult population 
against HBV infection it is unlikely that the number of CHB cases among FGM will 
rapidly decline in the near future in the Netherlands. Previous studies concluded 
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that systematic screening for HBV or combined screening for HBV and HCV in the 
Netherlands is cost-effective for most first generation migrant groups and even cost-
effective for FGM originating from countries with a HBV seroprevalence far below 
the cut-off of 2.0%, used by the Dutch Health Council to recommend screening.71,72
2.3 Recommendations for practice and further research
Case finding of individuals who are asymptomatic hepatitis B carriers in order to refer 
and treat them, is essential to reduce HBV related disease morbidity. An additional 
test policy is needed after case finding of HBV–infected healthcare workers who 
performs exposure prone procedures, to maintain patient safety. Based on our 
results we recommend a more tailored retest policy to monitor the viremia in HBV–
infected healthcare workers. This includes standard retesting every 6 months, with 
more frequent retesting just below the high threshold value (1 ×105 copies/mL) and 
prolonging this interval to 1 year after 3 consecutive levels below the threshold in 
policies with lower safety values (1 ×103, or 1 ×104 copies/mL).
To facilitate HBV case finding in the Netherlands, sexual health centres should 
be seen as an important health setting to detect CHB patients. At these centres case 
finding it is relatively easy and the emphasis should be on MSM and FGM originating 
from high endemic countries for sexually transmitted infections. Further research 
should explore if the full potential of SHCs are used in case finding, as the necessary 
infrastructure is in place for certain groups at risk for CHB.
As migrant groups are the largest contributor of CHB in the Netherlands and 
screening for HBV is cost-effective for FGM, a pro-active approach in case finding 
towards this group should be developed. In the absence of a national HBV screening 
program for FGM, three regions in the Netherlands started a pilot screening 
programme for viral hepatitis targeting foreign born migrants to improve the reach 
of screening activities among FGM and explore best-practices. The results of these 
best-practices should be disseminated nation-wide to improve the reach of these 
activities. Exploring further opportunities in systematic or opportunistic screening 
for migrant groups is needed to reduce the burden of disease for CHB.
3 Concluding remarks
Although HBV as a notifiable infectious disease is better under control in last decades, 
this thesis proves we are still able to optimise our control efforts through vaccination 
and case finding. This thesis provides two key recommendations in the revaccination 
of non-responders; first, the vaccines of choice are a vaccine with a higher antigen 
dose or a monophosphoryl lipid A-adjuvanted vaccine. These vaccines are not yet 
registered for this indication and this omission should be resolved. Second, the 
differentiated baseline anti-HBs titre should be used to determine the number of 




From a public health perspective, case finding of CHB and linkage to treatment 
will affect the burden of disease of hepatitis B to a far greater extent. Therefore, 
the advice of the Dutch Health Council to offer first-generation migrants from 
hepatitis B endemic countries screening for HBV is welcome. However, we would 
extend the advice to add case finding at sexual health centres and explore other 
out-reach screening opportunities. Lastly, commence the systematic screening of 
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Hepatitis B is a viral infection that affects the liver and can cause both acute and 
chronic disease. The studies described in this thesis aim to reduce the burden of 
disease caused by the hepatitis B virus. The main thesis research questions originated 
on the one hand from day-to-day practice of infectious disease control from public 
health services in the Netherlands and on the other hand from ongoing prevention 
programs against hepatitis B in the Netherlands. In this way these research questions 
were integrated in the infectious disease control in the Netherlands, which is a 
collaboration between several regional (e.g. public health services and laboratories 
of medical microbiology) and national (e.g. Centre for infectious disease control as 
part of the National Institute for Public health and the Environment) institutions.
Chapter 2 describes a vaccination program against hepatitis B among people who 
use drugs in the Netherlands. We used used data for behavioural risk groups from 
the register of the national vaccination program that provided information about 
baseline characteristics of participants and the vaccinations given. In a retrospective 
study we reported on factors associated with completing a standard series of three 
vaccinations against hepatitis B virus. Over the course of ten years, of the 15,746 
participants eligible for vaccination (i.e. they were neither carriers of hepatitis B nor 
immune to hepatitis B), 58% completed a series of three hepatitis B vaccinations. 
Our results suggest that flexibility of vaccination location and administration of 
vaccines by healthcare workers with sustainable contact with PWUD could improve 
vaccination programs for this risk group.
Antibodies against hepatitis B surface antigen (anti-HBs) of 10 IU/L or more is 
a correlate of protection against clinically relevant hepatitis B infections after 
vaccination. In chapter 3 we assessed the performance of currently used and 
commercially available anti-HBs diagnostic assays around the clinically relevant cutoff 
values of 10 IU/l and 100 IU/l. We used data from an external quality assessment 
program that sent pooled anti-HBs serum samples in different concentrations to 
various laboratories in the Netherlands. Results form six assays used by 42 laboratories 
were included in the sensitivity, specificity and agreement analysis. As a gold 
standard lacked, a true positive or true negative result was defined as an anti-HBs 
titre respectively above or below the cutoff value by at least 4 or more of the 6 assays. 
Around a cutoff value of 10 IU/l use of the Access assay may result in false-negative 
results. Concerning the cutoff value of 100 IU/l, a sample being classified below or 
above this cutoff relied heavily on the specific assay used, with both the Architect 
and the Access resulting in false-negative results.
Non-protective immunity after a standard hepatitis B vaccination series occurs in 
5 to 30% of healthy adults, depending on age and sex. Dutch guidelines recommend 
that these so called ‘non-responders’ are administered three revaccinations of 
a standard vaccine at months 0, 1, and 2. In chapter 4 we present the results of 
a randomized controlled trial that compares the standard revaccination series 
(HBVaxPro 10 µg or Engerix-B 20 µg) as the control to the Twinrix 20 µg, Fendrix 
20 µg, or HBVaxPro 40 µg revaccination series in non-responders after hepatitis B 
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vaccination. We randomized 480 participants from 13 regional health services and 
three academic centres in this multicentre trial. Most non-responders after a primary 
vaccination series reached protective antibody concentrations against hepatitis B 
after three revaccinations. Compared with the control group, the percentage of 
responders was superior for the HBVaxPro-40 group (adjusted difference 21·6% 
[95% CI 10·4–32·7], p=0·0204 and the Fendrix group (26·3% [15·4–37·3], p=0·0006), 
but not the Twinrix group (25·0% [13·0–37·0]; p=0·0846). Revaccination with Fendrix 
or HBVaxPro-40 resulted in significantly higher antibody titres and proportions 
of responders than revaccination with Engerix-B or HBVaxPro-10 and therefore 
indication for these vaccines should be expanded to enable revaccination of non-
responders.
In chapter 5 we assessed the comparability of four anti-HBs assays in in non-
responders and the effectiveness of a revaccination strategy guided by the height 
of the anti-HBs titre. In this study we tested samples of non-responders after 
hepatitis B vaccination with four frequently used anti-HBs diagnostic assays in the 
Netherlands. Inter-assay agreement of non-responders between the classification of 
zero-responders (anti-HBs titre below the limit of detection) and poor-responders 
(detectable anti-HBs titre) was fair with an k ≥ 0.65 except for the Advia (k ≤ 0.41). 
However, all assays demonstrated a comparable large difference in proportion 
of responders between zero- and poor-responders after one revaccination. This 
difference in proportion of responders was non-significant after three revaccinations. 
The classification of non-responders based on the anti-HBs titre is informative and 
should be specified by laboratories. This enables a titre-based revaccination schedule 
for a more efficient revaccination strategy in hepatitis B non-responders.
Case finding of patients with chronic hepatitis B (CHB) is one of the priority 
actions to reduce the burden of disease. In chapter 6 we used data from a nation-
wide network of Sexual Health Centres (SHCs) that provide low threshold, and 
free of charge, STI/HIV testing and care for high-risk groups. We determined the 
characteristics of CHB patients detected at SHCs and estimated the contribution of 
SHCs in CHB case finding compared to the number of CHB notified patients in the 
Netherlands. SHC consultations between January 1, 2008 to December 31, 2016 were 
included for this study (n=405,646). 1452 patients with positive HBsAg serology were 
detected of whom 87% were among first generation migrants (FGM) originating from 
high-endemic countries for sexually transmitted infections or men who have sex with 
men (MSM). The contribution of HBV patients detected at SHCs compared to the total 
number of nationally notified CHB patients ranged between 12.4% (200/1613) in 2008 
and 10.8% (106/980) in 2016. The contribution of SHCs is structural and relevant to 
case finding of CHB in the Netherlands. SHCs should therefore be considered as an 
important health setting to screen for HBV in high-risk groups, especially among MSM 
and FGM originating from high endemic countries for sexually transmitted infections, 
to achieve a reduction in the burden of HBV related disease.
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In chapter 7 we report on the dynamics of HBV viremia among notified HCWs 
with chronic hepatitis B infection in the Netherlands, who perform exposure 
prone procedures (EPPs). These procedures contain an increased risk of the HCW 
experiencing a percutaneous injury, thus exposing the patient to the HCW’s 
blood. Based on the results of 45 HCWs that had 2 or more HBV DNA levels tested 
without antiviral therapy, we determined the consequences for preventive policies, 
considering various HBV DNA safety thresholds, above which an infected HCW is not 
allowed to perform EPPs. Based on the results of this study, we propose standard 
retesting every 6 months, with more frequent retesting just below the high threshold 
value (1×105 copies/mL), and prolonging this standard interval to 1 year after 3 
consecutive levels below the threshold in policies with lower safety thresholds.
In Chapter 8 we present the main findings of this thesis. We discuss our results 
and provide recommendations and future policy directions for prevention strategies 
on hepatitis B. In addition, we put these in the perspective of recent literature and 
future research. Although HBV as a notifiable infectious disease is better under control 




De onderzoeken gepresenteerd in dit proefschrift hebben betrekking op 
het voorkomen en het beperken van de ziektelast van hepatitis B. De 
onderzoeksvragen voor dit proefschrift komen enerzijds voort uit praktijkvragen 
van de infectieziektebestrijding en anderzijds voort uit eerder opgezette 
preventieprogramma’s rondom hepatitis B in Nederland. Hiermee zijn deze 
onderzoeken ingebed in de praktijk van de infectieziektebestrijding die in Nederland 
in belangrijke mate wordt vormgegeven in een samenwerking tussen regionale 
GGD’en, laboratoria voor medische microbiologie en het RIVM.
Hoofdstuk 2 richt zich op een hepatitis B vaccinatieprogramma dat tussen en 
2002 en 2011 werd aangeboden aan personen die drugs gebruiken in Nederland. 
Hierbij is gebruik gemaakt van de landelijke database van dit vaccinatieprogramma 
waarin o.a. demografische gegevens en risicogedrag van deelnemers werd 
geregistreerd, naast data over de gegeven vaccinaties. Hierin is retrospectief gekeken 
naar welke factoren van belang zijn om een vaccinatieserie af te ronden. In 10 jaar tijd 
kwamen 15746 deelnemers in aanmerking voor een vaccinatieserie tegen hepatitis 
B waarvan 58% van de deelnemers de serie afmaakte. Naast enkele persoons- en 
gedragskenmerken zoals oudere leeftijd en intraveneus drugsgebruik waren ook 
organisatorische factoren zoals flexibiliteit in de locatie waar de vaccinatie werd 
gegeven en het type organisatie dat de vaccinatie uitvoerde geassocieerd met het 
afmaken van de vaccinatieserie.
Antistoffen tegen het hepatitis B oppervlakte antigeen (anti-HBs) zijn gecorreleerd 
met bescherming tegen hepatitis B na vaccinatie. In hoofdstuk 3 onderzoeken we of 
er klinisch relevante verschillen bestaan tussen assays die de anti-HBs titer bepalen 
rondom de afkapwaarden van 10 IU/l en 100 IU/l. Hiervoor zijn gegevens gebruikt 
van de SKML-kwaliteitsrondzendingen waarbij anti-HBs samples in verschillende 
concentraties naar meerdere laboratoria zijn gestuurd in Nederland en enkele landen 
daarbuiten. Gegevens van 6 assays gebruikt in 42 laboratoria zijn gebruikt om de 
sensitiviteit en specificiteit van het assay en de overeenkomst in uitslagen tussen 
de assays te bepalen. Omdat een gouden standaard ontbreekt definieerden we een 
‘correcte’ uitslag boven of onder een specifieke afkapwaarde wanneer tenminste 4 
van de 6 assays een waarde respectievelijk boven of onder deze afkapwaarde gaven. 
Het gebruikte assay om een anti-HBs titer te kwantificeren was bepalend, met name 
bij hogere anti-HBs titers rondom 100IU/l, voor de hoogte van de titer. Discrepantie 
tussen assays resulteerde voor twee assays in een fout-negatief resultaat. Rond de 
afkapwaarde van een anti-HBs titer van 10 IU/l gaf het Acces (Beckmann-Coulter) 
assay een fout-negatief resultaat en bij een afkapwaarde van 100IU/l betroffen dit 
de assays Acces (Beckmann-Coulter) en Architect (Abbott Laboratories).
Afhankelijk van de leeftijd en geslacht is 5% tot 30% van de gevaccineerde 
volwassenen na een eerste serie van drie vaccinaties tegen hepatitis B niet 
beschermd. Volgens de huidige Nederlandse richtlijn wordt aanbevolen om 
deze ‘non-responders’ nogmaals driemaal te vaccineren met een regulier vaccin. 
In hoofdstuk 4 presenteren we de resultaten van een gerandomiseerd klinisch 
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onderzoek waarbij het vaccinatieschema van de huidige richtlijn (controlegroep) is 
vergeleken met een overeenkomend vaccinatieschema met drie alternatieve hepatitis 
B vaccins in non-responders. 480 deelnemers werden gerekruteerd bij 13 GGD’en 
en drie academische centra en werden in deze multicenter studie gerandomiseerd 
over de 4 onderzoeksarmen. Het merendeel van de non-responders heeft na 3 
revaccinaties een beschermende anti-HBs titer boven de 10I/l. In vergelijking met 
de controlegroep lag het percentage responders hoger voor de deelnemers die met 
HBVaxPro-40 en Fendrix waren gevaccineerd met een gecorrigeerd verschil van 
respectievelijk 21.6% (95% CI 10.4–32.7) en 26.3% (95% CI 15.4–37.3). Deze bevinding 
onderbouwt het advies om het indicatiegebied voor de vaccins HBVaxPro-40 en 
Fendrix uit te breiden naar non-responders.
In hoofdstuk 5 onderzoeken we de hypothese of een beleid voor non-responders 
na een hepatitis B vaccinatieserie gebaseerd op de hoogte van de anti-HBs titer 
effectief is. Hiervoor hebben we bloedsamples van non-responders getest met vier 
veel voorkomende assays in Nederland voor de bepaling van anti-HBs titers. Voor 
drie van de vier assays kwam de indeling van non-responders in zero-reponders 
(anti-HBs waarde onder de detectiegrens) en poor-responders (anti-HBs waarde 
boven de detectiegrens) vrij goed overeen met een k ≥ 0.65. Desondanks, lieten 
alle assays een groot en overeenkomstig verschil in percentage responders zien 
tussen zero- en poor-responders na één revaccinatie dat verschil verdwijnt na drie 
revaccinaties. De hoogte van de anti-HBs titer is daarmee voor deze assays in hoge 
mate voorspellend voor het aantal revaccinaties bij non-responders na hepatitis B 
vaccinatie. We adviseren om die reden de hoogte van de anti-HBs titer te gebruiken 
in het revaccinatiebeleid bij non-responders en dat laboratoria de anti-HBs uitslag 
bij non-responders kwantificeren tussen de detectiegrens en de 10 IU/l.
In hoofdstuk 6 worden gegevens van een nationale database van SOA-centra 
in Nederland gebruikt om bij deze centra de patiënten opgespoord met chronische 
hepatitis B in kaart te brengen. Het hoogste aantal patiënten met chronische hepatitis 
B werd gevonden bij personen die als 1ste generatie migrant afkomstig waren uit 
landen met een verhoogde prevalentie voor SOA’s, MSM en sekswerkers. Voor 
bezoekers van de SOA-centra was chronisch hepatitis B dragerschap geassocieerd 
met personen die sekswerker waren, een hogere leeftijd hadden of een migratie-
achtergrond hadden. Afhankelijk van de seksuele voorkeur en het geslacht was 
chronisch hepatitis B dragerschap daarnaast geassocieerd met een co-infectie met 
HIV en een eerdere infectie met chlamydia, gonorroe of syfilis. Jaarlijks werden 
ongeveer 1 op 10 patiënten die in Nederland met chronische hepatitis B zijn gemeld, 
vastgesteld door SOA-centra. Dit aandeel bleef over 10 jaar tijd constant. Deze 
bevindingen benadrukken het belang van SOA-centra bij het screenen op hepatitis 
B in hoog-risico groepen, waarbij de activiteiten met name gericht zouden moeten 
zijn op MSM en 1ste generatie migranten.
In hoofdstuk 7 onderzoeken we hoe de viremie over de tijd fluctueert bij 
medisch personeel met een chronische hepatitis B infectie, die risicovolle medische 
170
Appendices
handelingen verrichten. Dit zijn medische handelingen waarbij risico op bloed-bloed 
contact tussen zorgverlener (‘risicovormer’) en patiënt groot is. De opeenvolgende 
HBV DNA waarden van 45 medische professionals werden retrospectief geanalyseerd 
om risicofactoren en de tijdsduur te bepalen waarbij een overschrijding van de viral 
load optrad boven een grens van 1x105 copies/ml. Enkel de hoogte van de viremie 
was bepalend voor het overschrijden van de bovengrens. Medisch personeel met 
chronische hepatitis B kan in de zorg risicovormende handelingen verrichten mits 
de viral load onder de 1x105 copies/ml blijft. De resultaten van deze studie geven aan 
dat de tijdsduur tussen twee controles van de viremie standaard elk half jaar dient 
plaats te vinden waarbij in een aantal situaties deze termijn kan worden aangepast 
afhankelijk van de hoogte van de viral load.
In hoofdstuk 8 worden de belangrijkste bevindingen van dit proefschrift 
samengevat en besproken. Daarbij worden de bevindingen geplaatst in de context 
van de recente literatuur en worden aanbevelingen gedaan voor toekomstig 
beleid en onderzoek. Samenvattend is het bestrijdingsbeleid voor hepatitis B in de 
afgelopen 20 jaar verbeterd, maar laat dit proefschrift zien dat op het gebied van (re)






In 2016 the World Health Organization (WHO) published the report ‘Viral hepatitis 
2016-2021 – towards ending of viral hepatitis’ comparing viral hepatitis with other 
major communicable disease problems such as HIV, Malaria and Tuberculosis. To 
reduce the burden of disease of viral hepatitis WHO defined a set of priority actions. 
Targets for HBV were set at 95% reduction of new cases and 65% reduction in 
mortality by 20304 and WHO urged all countries to develop a national strategy to 
stop further transmission reduce the mortality and morbidity related to viral hepatitis. 
Based on the report the National Institute for Public Health and the Environment 
developed a National plan which scope it is to enhance initiatives regarding hepatitis 
control according to several themes (among others reduction of transmission through 
awareness and vaccination and identification). Chapters 2-5 matches the objective 
of the national plan on reduction of transmission through vaccination. The results 
of these chapters could be of interest for organizations involved in vaccination of 
adult risk groups for hepatitis B such as physicians working in infectious disease 
control, occupational physicians, addiction care professionals. As, in an adult 
population, depending on age and sex, 5% to 30% will not mount a protective 
immune response after vaccination, healthcare professionals will regularly encounter 
a non-responder after hepatitis B vaccination. We propose in this thesis an improved 
revaccination scheme for non-responders and offer a revaccination strategy based 
on a differentiated anti-HBs titre that results in a substantial reduction of vaccine 
use and vaccination consultations compared to the current revaccination policy. In 
addition chapter 2 describes some factors associated with better completion of a 
vaccination series in people who use drugs which can be used by addiction care 
facilities responsible for the vaccination of people who inject drugs.
All studies in this thesis were conducted in the light of this aim to reduce the burden of 
disease caused by the hepatitis B virus. The main thesis research questions originated 
on the one hand from day-to-day practice of infectious disease control from public 
health services in the Netherlands and on the other hand from ongoing prevention 
programs against hepatitis B in the Netherlands. These research questions are 
embedded in the infectious disease control which is a collaboration between regional 
(public health services and laboratories) and national (Centre for Infectious Disease 
Control as part of the National Institute for Public Health and the Environment) 
institutions. Consequently the findings from our studies have in addition to a 
scientific, also a value for infectious disease control guidelines of hepatitis B and the 
policy regarding primary and secondary prevention programs of hepatitis B.
For example, we used the information from chapter 4 to inform the National 
Platform of Infectious Disease Control (LOI) that is authorized to define guidelines 
of infectious disease control in the public health (‘LCI-richtlijnen) in the Netherlands. 
We planned a revision of the paragraph regarding non-responders of the guideline 
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‘Hepatitis B’ based on the information from chapter 4 and 5 which was not completely 
available at the time of the first meeting.
The results and recommendations from chapter 7 were addressed to the Dutch 
Committee for Prevention of Iatrogenic Hepatitis B to reconsider their policy on 
exposure prone procedures for healthcare workers infected with hepatitis B.
Target groups
In general the recommendations made on the hepatitis B (re)-vaccination policy 
and case finding of chronic hepatitis B patients is first of all of importance for 
public health professionals and policy makers. More specifically, public health 
professional, infectious disease specialists and policy makers involved on a national 
or regional level to reduce the mortality and morbidity related to viral hepatitis. The 
recommendations made regarding the vaccination policy are also of importance to 
all medical professionals that vaccinate risk groups against hepatitis B. For example, 
general practitioners, occupational practitioners and professionals in the field of 
addiction care or travel medicine.
Strengthen the public health services
The results from chapter 3, 4 and 5 provide information to extent the knowledge 
base on hepatitis B vaccination in a more individualistic approach. The choice of 
vaccine and number of revaccinations depend on the individual characteristics and 
serological response. This individual revaccination approach fits in a development 
of regional health services to offer several vaccines, outside of national vaccination 
programs and travel consultations, to individuals with an indication for that vaccine 
(‘Targeted vaccination’ or in Dutch ‘Vaccinaties op maat’). One of the novel research 
ideas is to further explore the influence of previous immunity of hepatitis A on the 
serological response of non-responders to hepatitis B vaccination. This will provide 
insights on a more targeted use of a combined hepatitis A and hepatitis B vaccine 
in the policy for non-responders after hepatitis B vaccination. Ultimately, the results 
of these studies will strengthen the available knowledge to use hepatitis B vaccines 
more tailored to the patient and enable the development of ‘targeted vaccination’ 
in public health services.
Since 2005, initially with funding from ZonMw, a collaboration between regional 
health services and academic centres ‘Academische werkplaats Publieke Gezondheid’ 
(AWP) started in the Netherlands. This collaboration reinforced contacts between 
these institutions to bridge the gap between the triangle of research, practice and 
policy in the field of public health. This collaboration provided an impetus to answer 
practice-based research questions of regional health services which is indispensable 
for the transformation of practice-based medicine into evidence-based medicine. 
The study described in chapter 4 was a collaboration of three AWPs and took an 
advantage of this growing network of public health services and academic centres. 
The study was also innovative as it modified the daily practice of a regional health 
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service by a few additional actions into a randomized trial. As it was a multicentre 
study, this enabled multiple regional health services to experience the conduct of a 
research question in practice. The study might as well demonstrate how to organise 




Wanneer het precies begon weet ik niet meer, maar sinds ongeveer twee jaar passeren 
tijdens het hardlopen steeds dezelfde vragen in mijn hoofd. Lig ik op schema? Zou de 
editor me vergeten zijn? Wat zijn m’n mogelijkheden om deze week aan onderzoek 
te werken? Waarom heb ik twee werkgevers? Waarom wil ik dit zo graag?
Het antwoord op die laatste vraag is me overigens duidelijk. Niet alleen geeft het 
doen van onderzoek me de grootste werkfrustratie, ook haal ik hier de meeste 
voldoening uit en heeft het me gevormd in m’n werkzaamheden binnen de 
infectieziektebestrijding. Onderzoek kun je niet alleen doen en alle positieve aspecten 
waren nooit tot stand gekomen zonder de fijne samenwerking met vele collega’s.
Allereerst mijn promotoren en co-promotoren. Het was een voorrecht met jullie te 
mogen samenwerken. Jullie waren als een estafette-team waarbij in Den Bosch op 
hoofdlijnen het proefschrift vorm kreeg en gedurende de jaren steeds op het goede 
moment het stokje in begeleiding werd doorgegeven. Daarbij bleven jullie altijd 
meelopen, een hele prestatie gezien de lengte van mijn traject. In volgorde van 
kennismaking:
Beste Jeannine Hautvast, veel dank dat ik mijn eerste onderzoek bij AMPHI heb 
mogen uitvoeren. Dit vormde het begin van een mooie samenwerking. Bij AMPHI 
heb ik me altijd thuis gevoeld. Ik waardeer je zorgvuldige commentaren en je wist 
met je scherpe blik en logica elke binnenbocht in mijn tekst naar boven te halen. 
Bedankt voor het vertrouwen dat je me gaf om verder te gaan met het uitvoeren 
van praktijkgericht onderzoek.
Beste Jim van Steenbergen, vanaf de eerste kennismaking was elk werkoverleg steeds 
een klein feest. Je gaf niet alleen antwoord op de vragen waar ik mee zat, maar 
gaf tegelijkertijd een beschouwing over het te bespreken onderwerp. Die aanpak 
was erg stimulerend en verrijkt met nieuwe ideeën kon ik weer aan de slag. Je hebt 
je uitgebreide netwerk binnen de infectieziektebestrijding voor me opengesteld, 
waardoor ik bij elke deelvraag met de juiste mensen kon samenwerken. Ook al waren 
veel overleggen op afstand, je hoorde ook de dingen die ik niet uitsprak. Daar heb 
ik veel van geleerd.
Beste Christian Hoebe, bedankt dat in Maastricht mijn promotie-onderzoek een plek 
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